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1.	  Abstract	  
	  
Most	  pathogens	  invade	  their	  human	  host	  or	  establish	  infection	  at	  mucosal	  surfaces.	  In	  
contrast	  to	  parenteral	  vaccines,	  mucosal	  immunization	  has	  the	  potential	  to	  induce	  a	  robust	  
immune	  response	  at	  mucosal	  surfaces	  capable	  of	  blocking	  the	  entry	  and	  establishment	  of	  
many	  pathogens.	  Despite	  these	  advantages,	  very	  few	  mucosal	  vaccines	  are	  licensed	  for	  
human	  use,	  largely	  because	  antigens	  administered	  by	  the	  mucosal	  route	  are	  either	  poorly	  
or	  non-­‐immunogenic.	  A	  strategy	  to	  overcome	  this	  problem	  is	  co-­‐administering	  vaccine	  
antigens	  with	  a	  mucosal	  adjuvant.	  Recently,	  bis-­‐(3’,5’)-­‐cyclic	  dimeric	  adenosine	  
monophosphate	  (c-­‐di-­‐AMP)	  was	  identified	  as	  a	  potential	  mucosal	  adjuvant.	  To	  evaluate	  c-­‐
di-­‐AMP	  as	  a	  mucosal	  adjuvant	  two	  studies	  were	  conducted:	  The	  first	  characterized	  the	  
immune	  responses	  elicited	  by	  c-­‐di-­‐AMP	  when	  used	  as	  a	  sublingual	  and	  intranasal	  adjuvant;	  
and	  the	  second	  tested	  the	  protective	  efficacy	  of	  c-­‐di-­‐AMP	  in	  a	  vaccine	  model	  of	  hookworm	  
pathogenesis.	  From	  our	  studies,	  c-­‐di-­‐AMP	  stimulates	  strong	  humoral	  and	  cellular	  immune	  
responses,	  and	  induces	  a	  predominately	  Th1/Th17	  T	  cell	  response	  pattern,	  as	  shown	  by	  
elevated	  expression	  of	  IgG2a	  and	  enhanced	  secretion	  of	  IFN-­‐γ,	  IL-­‐17,	  and	  IL-­‐22.	  Despite	  
these	  successes,	  when	  tested	  in	  a	  hookworm	  vaccine	  model	  c-­‐di-­‐AMP	  failed	  to	  significantly	  
enhance	  the	  protective	  efficacy	  of	  hookworm	  excretory-­‐secretory	  (ES)	  antigens.	  However,	  
we	  did	  discover	  that	  ES	  antigens	  alone,	  given	  intranasally,	  confer	  a	  73.8%	  reduction	  in	  
adult	  worm	  burden,	  and	  appear	  to	  modulate	  the	  severity	  of	  hookworm-­‐associated	  anemia	  
and	  weight	  loss.	  We	  hypothesize	  that	  part	  of	  this	  success	  is	  due	  to	  inherent	  adjuvant	  
properties	  of	  ES,	  which	  boost	  the	  immunogenicity	  of	  vaccine	  relevant	  antigens.	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2.	  Introduction	  
Most	  infectious	  agents	  enter	  the	  body,	  or	  establish	  infection,	  at	  mucosal	  surfaces,	  making	  
the	  mucosal	  immune	  system	  an	  important	  line	  of	  defense	  against	  human	  pathogens.1,	  2,	  3,	  4	  
However,	  most	  vaccines	  are	  administered	  by	  parenteral	  injection,	  which	  confer	  protection	  
by	  stimulating	  systemic	  immune	  responses,	  such	  as	  serum	  antibodies	  and	  in	  some	  cases	  
effector	  T	  cell	  responses,	  but	  are	  notoriously	  inefficient	  for	  stimulating	  primary	  immune	  
responses	  in	  mucosal	  tissues.3	  In	  contrast	  to	  these	  vaccines,	  mucosal	  vaccinations	  have	  the	  
potential	  to	  counter	  mucosa-­‐associated	  pathogens	  at	  the	  portal	  of	  entry	  by	  inducing	  local	  
pathogen-­‐specific	  immune	  responses,	  as	  well	  as	  systemic	  humoral	  and	  cellular	  responses.5	  
Traditionally,	  the	  oral	  and	  nasal	  routes	  have	  been	  used	  for	  mucosal	  immunization,	  but	  
other	  routes	  include	  the	  rectal,	  vaginal,	  sublingual,	  and	  transcutaneous	  routes,	  all	  of	  which	  
share	  the	  common	  goal	  of	  strengthening	  the	  first	  line	  of	  defense	  against	  human	  pathogens.4	  
The	  gastrointestinal,	  respiratory	  and	  urogenital	  tracts,	  eye	  conjunctiva,	  inner	  ear,	  
and	  ducts	  of	  all	  the	  exocrine	  glands	  are	  covered	  by	  mucous	  membranes	  endowed	  with	  
powerful	  mechanical	  and	  chemical	  cleansing	  mechanisms	  that	  repel	  and	  degrade	  most	  
foreign	  matter.4	  Additionally,	  they	  contain	  a	  number	  of	  other	  cells	  of	  the	  innate	  immune	  
system,	  including	  phagocytic	  neutrophils	  and	  macrophages,	  dendritic	  cells	  (DCs),	  natural	  
killer	  (NK)	  cells	  and	  mast	  cells.	  Through	  a	  variety	  of	  mechanisms	  these	  cells	  contribute	  
significantly	  to	  host	  defense	  against	  pathogens	  and	  in	  initiating	  adaptive	  mucosal	  immune	  
responses.1	  The	  hallmark	  of	  adaptive	  mucosal	  immunity	  is	  the	  production	  of	  secretory	  
immunoglobulin	  A	  (IgA)	  antibodies.4	  Secretory	  IgA	  functions	  not	  only	  by	  preventing	  
attachment	  to	  or	  translocation	  of	  pathogens	  across	  epithelial	  cells	  but	  also	  by	  limiting	  their	  
transmission	  from	  person-­‐to-­‐person.3	  While	  IgA	  is	  the	  predominant	  humoral	  defense	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mechanism	  at	  mucosal	  surfaces,	  locally	  produced	  IgM	  and	  IgG	  also	  contribute	  to	  host	  
defense.1	  Additionally,	  the	  mucosal	  immune	  system	  contains	  cytotoxic	  T	  lymphocytes	  
(CTLs),	  crucial	  for	  the	  clearance	  of	  many	  enteric	  viruses,	  respiratory	  viruses	  and	  
intracellular	  parasites,6,	  7,	  1	  and	  interferon	  (IFN)-­‐γ-­‐producing	  CD4+	  T	  cells	  that	  have	  been	  
found	  to	  be	  important	  for	  defense	  for	  mucosa-­‐associated	  viral	  and	  bacterial	  infections.1,	  12	  	  
Contrary	  to	  parenteral	  vaccines,	  mucosal	  vaccination	  has	  the	  unique	  ability	  to	  
leverage	  these	  responses	  to	  induce	  ‘frontline	  immunity,’	  preventing	  the	  establishment	  and	  
dissemination	  of	  mucosa-­‐associated	  pathogens.8	  Additionally,	  mucosal	  vaccination	  offers	  
several	  logistical	  advantages	  over	  systemic	  vaccination.	  For	  one,	  mucosal	  vaccination	  does	  
not	  require	  injection,	  which	  makes	  administration	  easier	  (including	  the	  possibility	  of	  self-­‐
administration),	  reduces	  the	  risk	  needle-­‐stick	  injuries,	  and	  has	  the	  potential	  to	  increase	  
compliance	  among	  people	  afraid	  of	  needles.9,	  5	  Furthermore,	  simplified	  manufacturing	  and	  
storage	  methods,	  as	  well	  as	  independence	  from	  trained	  medical	  personnel	  for	  delivery,	  
make	  mucosal	  vaccines	  suitable	  for	  mass	  vaccination	  programs,	  especially	  in	  developing	  
countries	  and	  during	  emergency	  situations.8,	  4	  
Despite	  the	  many	  attractive	  features	  of	  mucosal	  vaccination,	  only	  7	  mucosal	  
vaccines	  have	  been	  licensed	  for	  human	  use,	  with	  only	  4	  approved	  for	  use	  in	  the	  US	  (Table	  
1).1,	  4	  These	  vaccines	  target	  five	  of	  the	  main	  enteric	  pathogens	  —	  poliovirus,	  Vibrio	  
cholerae,	  Salmonella	  typhi,	  rotavirus	  —	  and	  influenza.	  As	  shown	  in	  Table	  1,	  the	  majority	  of	  
these	  vaccines	  are	  based	  on	  live	  attenuated	  formulations;	  and	  with	  the	  exception	  of	  
FluMist®,	  all	  of	  them	  are	  orally	  administered.	  Typically,	  attenuation	  involves	  propagation	  of	  
a	  pathogen	  under	  novel	  conditions	  so	  that	  it	  becomes	  less	  pathogenic	  to	  its	  original	  host,	  
while	  still	  being	  able	  to	  elicit	  a	  robust	  protective	  immune	  response	  to	  the	  wild-­‐type	  strain.	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Attenuation,	  however,	  is	  a	  largely	  unpredictable	  process,	  and	  on	  occasion	  successfully	  
attenuated	  pathogens	  may	  revert	  back	  to	  virulence.10	  The	  best	  example	  of	  this	  is	  the	  oral	  
polio	  vaccine	  (OPV).	  Introduced	  in	  1955,	  OPV	  is	  the	  classic	  oral-­‐mucosal	  vaccine.	  Similar	  to	  
its	  alternative,	  the	  injectable	  inactivated	  polio	  vaccine	  (IPV),	  OPV	  induces	  systemic	  
antibody	  production	  that	  protects	  against	  poliomyelitis	  by	  preventing	  the	  spread	  of	  
poliovirus	  to	  the	  nervous	  system,	  but	  superior	  to	  IPV,	  OPV	  also	  induces	  local	  secretory	  IgA	  
in	  the	  intestinal	  mucosa	  capable	  of	  blocking	  colonization,	  and	  thus	  limiting	  person-­‐to-­‐
person	  transmission	  through	  the	  fecal-­‐oral	  route.1	  Unfortunately,	  though,	  on	  rare	  occasions	  
the	  vaccine	  strains	  (i.e.,	  Sabin	  1,	  2,	  and	  3)	  have	  been	  known	  to	  revert	  back	  to	  
neurovirulence	  causing	  vaccine-­‐associated	  paralytic	  poliomyelitis	  (VAPP),	  a	  condition	  
	   9	  
virtually	  identical	  to	  the	  wild-­‐type	  paralytic	  poliomyelitis.	  The	  incidence	  of	  VAPP	  is	  
estimated	  at	  4	  cases	  per	  1,000,000	  births	  per	  year,	  which	  has	  led	  to	  the	  replacement	  of	  OPV	  
by	  IPV	  in	  most	  industrialized	  countries.11	  
To	  circumvent	  this	  issue,	  researchers	  have	  begun	  to	  design	  vaccines	  based	  on	  a	  
limited	  number	  of	  highly	  purified	  recombinant	  molecules	  or	  pathogen	  subunits.5,	  13	  This	  
strategy	  has	  greatly	  improved	  the	  overall	  safety	  of	  vaccines,	  but	  as	  a	  consequence	  vaccine	  
antigens	  have	  lost	  their	  inherent	  immunostimulatory	  properties	  and	  often	  do	  not	  elicit	  
strong	  immune	  responses.5	  The	  problem	  is	  even	  worse	  when	  antigens	  are	  administrated	  
mucosally	  where	  they	  are	  forced	  to	  contend	  with	  the	  unique	  characteristics	  of	  the	  mucosal	  
environment,	  including	  the	  presence	  of	  mucus,	  limited	  antigen	  uptake,	  and	  the	  possibility	  
of	  antigen	  degradation.5	  Moreover,	  unlike	  the	  systemic	  immune	  apparatus,	  which	  functions	  
in	  a	  normally	  sterile	  milieu	  and	  often	  responds	  vigorously	  to	  invaders,	  the	  mucosa-­‐
associated	  lymphoid	  tissues	  guard	  organs	  that	  are	  replete	  with	  foreign	  matter.	  Therefore,	  
the	  mucosal	  immune	  system	  has	  to	  economically	  select	  appropriate	  effector	  mechanisms	  
and	  regulate	  their	  intensity	  to	  avoid	  bystander	  tissue	  damage	  and	  immunological	  
exhaustion.	  Consequently,	  highly	  purified	  vaccine	  antigens	  are	  often	  treated	  as	  any	  other	  
non-­‐pathogenic	  antigen	  (e.g.,	  food	  proteins)	  and	  channeled	  to	  default	  pathways	  usually	  
resulting	  in	  tolerance.1	  	  
Fortunately,	  to	  overcome	  these	  problems	  antigens	  can	  be	  co-­‐administered	  with	  
adjuvants	  (from	  adjuvare,	  “to	  help”),	  which	  are	  molecules,	  compounds	  or	  macromolecular	  
complexes	  that	  boost	  the	  potency	  and	  longevity	  of	  specific	  immune	  responses	  to	  antigens,	  
but	  cause	  minimal	  toxicity	  or	  lasting	  immune	  effects	  on	  their	  own.13,	  14	  In	  general,	  
adjuvants	  enhance	  T	  and	  B	  cell	  responses	  by	  engaging	  components	  of	  the	  innate	  immune	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system,	  rather	  than	  directly	  acting	  on	  lymphocytes	  themselves.13	  Microbial	  detection	  by	  the	  
innate	  immune	  system	  relies	  heavily	  on	  pattern	  recognition	  receptors	  (PRRs),	  which	  
recognize	  molecular	  structures	  common	  to	  large	  groups	  of	  microbes	  (i.e.,	  pathogen-­‐
associated	  molecular	  patterns,	  PAMPs).	  Members	  of	  nearly	  all	  of	  the	  PRR	  families	  are	  
potential	  targets	  for	  adjuvants.	  These	  include	  Toll-­‐like	  receptors	  (TLRs),	  NOD-­‐like	  
receptors	  (NLRs),	  RIG-­‐I-­‐like	  receptors	  (RLRs)	  and	  C-­‐type	  lectin	  receptors	  (CLRs).13,	  14	  By	  
co-­‐administering	  antigens	  (which	  are	  inefficient	  at	  engaging	  the	  innate	  immune	  system)	  
with	  adjuvants,	  these	  formulations	  are	  able	  to	  activate	  innate	  transcriptional	  programs	  that	  
result	  in	  the	  induction	  of	  genes	  encoding	  cytokines,	  chemokines,	  and	  costimulatory	  
molecules	  that	  play	  a	  key	  role	  in	  the	  priming,	  expansion,	  and	  polarization	  of	  adaptive	  
immune	  responses.14,	  13,	  15	  Thus,	  adjuvants	  can	  provide	  a	  crucial	  link	  between	  the	  innate	  
and	  adaptive	  immune	  systems	  by	  providing	  a	  proinflammatory	  environment	  that	  favors	  
the	  development	  of	  stronger	  and	  broader	  immune	  responses,	  and	  do	  not	  lead	  to	  tolerance.1	  	  
The	  concept	  that	  primary	  infection	  leads	  to	  immunity	  against	  subsequent	  infections	  
was	  the	  cornerstone	  for	  the	  development	  of	  first-­‐generation	  attenuated	  vaccines	  against	  
poliomyelitis,	  measles,	  and	  numerous	  other	  infections.16	  However,	  for	  a	  number	  pathogens	  
(e.g.,	  HIV,	  hepatitis	  C	  virus,	  herpes	  viruses,	  mycobacteria,	  and	  parasitic	  infections)	  natural	  
infection	  does	  not	  confer	  immunity.	  For	  these	  infections,	  a	  central	  challenge	  has	  been	  
developing	  unique	  strategies	  to	  stimulate	  artificial	  immune	  responses	  able	  to	  elicit	  
protection.16	  In	  these	  regards,	  adjuvants	  might	  be	  particularly	  useful,	  since	  in	  addition	  to	  
increasing	  the	  magnitude	  of	  the	  adaptive	  response,	  they	  are	  also	  able	  to	  guide	  the	  adaptive	  
immune	  response	  to	  elicit	  specific	  types	  of	  immune	  responses.	  For	  example,	  adjuvants	  have	  
been	  used	  in	  preclinical	  and	  clinical	  studies	  to	  elicit	  functionally	  appropriate	  types	  of	  
	   11	  
immune	  responses,	  such	  T	  helper	  1	  (Th1)	  versus	  Th2	  versus	  Th17	  responses,	  CD8+	  versus	  
CD4+	  T	  cell	  responses,	  and/or	  specific	  antibody	  isotype	  responses.13	  In	  this	  respect,	  a	  
strategy	  of	  mucosally	  administrating	  isolated	  protective	  antigens	  with	  appropriate	  
adjuvants	  may	  not	  only	  improve	  vaccine	  safety,	  but	  also	  offer	  new	  strategies	  for	  targeting	  
pathogens	  that	  have	  been	  refractory	  to	  vaccination	  thus	  far.13,	  2	  	  
Human	  hookworm	  infection	  is	  an	  example	  of	  a	  disease	  that	  might	  be	  particularly	  
suited	  for	  such	  a	  strategy.	  Hookworm	  disease	  is	  caused	  by	  infection	  with	  multiple	  species	  
of	  bloodfeeding	  intestinal	  parasitic	  nematodes;	  the	  most	  common	  being	  Ancylostoma	  
duodenale,	  Ancylostoma	  ceylanicum,	  and	  Necator	  americanus.	  Together,	  these	  organisms	  
are	  estimated	  to	  infect	  500-­‐800	  million	  people	  worldwide,	  including	  approximately	  126	  
million	  children,	  causing	  growth	  delay	  (especially	  in	  children)	  and	  anemia.17,	  18,	  19	  	  
Traditional	  control	  strategies	  have	  focused	  on	  community-­‐based	  treatment	  of	  high-­‐
risk	  populations	  (e.g.,	  school-­‐age	  children)	  with	  benimidazole	  anthelminthics.18	  However,	  
studies	  sponsored	  by	  the	  WHO,	  among	  other	  organizations,	  have	  shown	  high	  rates	  of	  
hookworm	  reinfection	  can	  occur	  within	  a	  few	  months	  following	  benzimidazole	  treatments.	  
Presumably,	  this	  is	  the	  result	  of	  the	  absence	  of	  acquired	  immunity,	  leaving	  individuals	  
susceptible	  to	  reinfection	  following	  exposure	  to	  third-­‐stage	  infective	  hookworm	  larvae	  (L3)	  
in	  the	  soil.16	  Additionally,	  there	  is	  concern	  about	  emerging	  anthelminthic	  drug	  resistance	  
among	  human	  hookworm	  populations.18	  Taken	  together,	  these	  issues	  necessitate	  a	  search	  
for	  alternative	  or	  complementary	  approaches	  to	  public	  health	  control	  that	  do	  not	  rely	  
exclusively	  on	  anthelminthics.16	  	  
One	  approach	  is	  the	  development	  and	  use	  of	  an	  anti-­‐hookworm	  vaccine.16	  The	  
hookworm	  life	  cycle	  begins	  when	  eggs	  excreted	  in	  the	  feces	  of	  an	  infected	  individual	  hatch	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in	  the	  soil,	  and	  undergo	  successive	  molts	  to	  the	  third	  larval	  stage	  (L3).	  Infection	  is	  most	  
frequently	  acquired	  when	  L3	  parasites	  penetrate	  the	  skin	  and	  enter	  the	  circulatory	  system	  
by	  invading	  small	  blood	  vessels	  or	  lymphatics.	  From	  there	  the	  larvae	  are	  carried	  passively	  
to	  the	  heart,	  and	  then	  the	  lungs	  where	  they	  traverse	  alveolar	  capillaries	  to	  enter	  the	  
respiratory	  system.	  After	  migrating	  up	  the	  trachea,	  larvae	  are	  swallowed	  and	  enter	  the	  
digestive	  system	  where	  they	  migrate	  to	  the	  small	  intestine	  to	  undergo	  a	  final	  molt	  into	  
blood-­‐feeding	  adults.19	  During	  host	  stages,	  the	  primary	  interface	  between	  the	  parasite	  and	  
the	  host	  is	  the	  excretory-­‐secretory	  (ES)	  component,	  a	  complex	  mixture	  of	  proteins,	  
carbohydrates,	  and	  lipids	  secreted	  from	  the	  surface	  or	  oral	  openings	  of	  the	  parasite.	  These	  
products	  orchestrate	  a	  wide	  range	  of	  activities	  that	  are	  thought	  to	  be	  crucial	  for	  their	  
survival	  and	  propagation,	  including	  penetration	  of	  the	  host,	  tissue	  invasion,	  feeding,	  
reproduction,	  and	  evasion	  of	  the	  host	  immune	  system.49	  Given	  the	  importance	  of	  the	  ES	  
component,	  and	  the	  extensive	  overlap	  between	  the	  hookworm’s	  lifecycle	  and	  the	  host’s	  
mucosa,	  a	  mucosal	  vaccine	  targeting	  ES	  antigens	  might	  be	  uniquely	  poised	  to	  confer	  
protective	  immunity.	  
As	  discussed	  earlier,	  adjuvants,	  and	  specifically	  mucosal	  adjuvants,	  will	  likely	  be	  
crucial	  for	  the	  successful	  development	  of	  such	  a	  vaccine.	  Unfortunately,	  despite	  assessment	  
of	  a	  large	  number	  of	  compounds,	  only	  three	  adjuvants	  are	  currently	  in	  widespread	  use	  in	  
humans:	  Alum,	  MF59™,	  and	  ASO4,	  and	  of	  these	  only	  Alum	  and	  ASO4	  are	  approved	  for	  
human	  use	  in	  the	  US.13	  Additionally,	  all	  of	  these	  adjuvants	  were	  designed	  for	  use	  in	  
parenteral	  vaccines,	  and	  none	  of	  them	  exhibit	  activity	  when	  administered	  by	  the	  mucosal	  
route.	  Thus,	  the	  lack	  of	  effective	  mucosal	  adjuvants	  represents	  a	  critical	  bottleneck	  in	  the	  
development	  of	  mucosal	  vaccines.5,	  9	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Recently,	  though,	  members	  of	  the	  cyclic	  di-­‐nucleotide	  family	  have	  emerged	  as	  
promising	  mucosal	  adjuvants.	  	  The	  first	  molecule	  explored	  was	  bis-­‐(3’,5’)-­‐cyclic	  dimeric	  
guanosine	  monophosphate	  (c-­‐di-­‐GMP),	  a	  small	  signaling	  molecule	  that	  is	  thought	  to	  act	  as	  a	  
danger	  signal	  to	  the	  host	  immune	  system.	  Using	  a	  mouse	  model,	  these	  initial	  studies	  
showed	  that	  c-­‐di-­‐GMP	  exhibits	  potent	  activity	  as	  an	  adjuvant	  when	  administered	  by	  
mucosal	  and	  systemic	  routes.20	  Further	  studies	  then	  identified	  bis-­‐(3’,5’)-­‐cyclic	  dimeric	  
inosine	  monophosphate	  (c-­‐di-­‐IMP)	  as	  a	  structurally	  related	  but	  distinct	  compound,	  which	  
is	  also	  able	  to	  enhance	  antigen-­‐specific	  immune	  responses	  following	  mucosal	  
immunization	  of	  mice.9	  And	  more	  recently,	  bis-­‐(3’,5’)-­‐cyclic	  dimeric	  adenosine	  
monophosphate	  (c-­‐di-­‐AMP)	  was	  identified	  as	  an	  additional	  candidate	  mucosal	  adjuvant.21	  
C-­‐di-­‐AMP	  was	  originally	  shown	  to	  be	  a	  bacterial	  second	  messenger	  that	  signals	  for	  DNA	  
integrity	  in	  Bacillus	  subtilis	  during	  sporulation,	  however,	  subsequent	  studies	  revealed	  that	  
it	  is	  wide-­‐spread	  throughout	  bacterial	  species,	  and	  may	  play	  a	  role	  in	  triggering	  the	  
cytosolic	  host	  response	  of	  innate	  immunity.21	  To	  evaluate	  c-­‐di-­‐AMP	  as	  a	  mucosal	  adjuvant	  
two	  studies	  were	  conducted:	  The	  first	  characterized	  the	  immune	  responses	  elicited	  by	  c-­‐di-­‐
AMP	  when	  used	  as	  a	  sublingual	  and	  intranasal	  adjuvant;	  and	  the	  second	  tested	  the	  
protective	  efficacy	  of	  c-­‐di-­‐AMP	  in	  a	  vaccine	  model	  of	  hookworm	  pathogenesis.	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3.	  Hypothesis	  &	  Specific	  Aims	  	  
3.1.	  Hypothesis	  	  
Bis-­‐(3’,	  5’)-­‐cyclic	  dimeric	  adenosine	  monophosphate	  (c-­‐di-­‐AMP)	  is	  a	  potent	  mucosal	  
adjuvant	  that	  elicits	  broad	  immune	  responses	  through	  both	  sublingual	  and	  intranasal	  
routes;	  and	  is	  able	  to	  enhance	  the	  protective	  efficacy	  of	  hookworm	  excretory-­‐secretory	  
(ES)	  antigens.	  	  	  	  
	  
3.2.	  Specific	  Aims	  
1. Characterize	  the	  adjuvant	  properties	  elicited	  by	  c-­‐di-­‐AMP	  through	  intranasal	  and	  
sublingual	  immunization	  of	  BALB/c	  mice	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4.	  Sublingual	  versus	  intranasal	  immunization	  using	  c-­‐di-­‐AMP	  as	  a	  mucosal	  adjuvant	  †	  
4.1.	  Methods	  
4.1.1.	  Animals	  
Immunization	  studies	  were	  conducted	  in	  6-­‐8	  week-­‐old	  female	  BALB/c	  mice	  of	  the	  H-­‐2d	  
haplotype	  (Harlan,	  Germany).	  All	  animal	  experiments	  were	  performed	  in	  agreement	  with	  
the	  government	  of	  Lower	  Saxony,	  Germany	  (No.	  33.11.42502-­‐04-­‐017/08).	  
	  
4.1.2.	  Bis-­‐(3’,5’)-­‐cyclic	  dimeric	  adenosine	  monophosphate	  (c-­‐di-­‐AMP)	  
Previously,	  c-­‐di-­‐AMP	  (C20H24N10O12P2)	  was	  synthesized	  by	  cyclization	  and	  purified	  by	  
reversed	  phase	  HPLC,	  according	  to	  established	  protocols.21	  The	  lyophilized	  compound	  was	  
stored	  at	  −20	  °C	  until	  use	  when	  it	  was	  resuspended	  in	  sterile	  water	  for	  the	  immunization	  
studies.	  The	  presence	  of	  LPS	  was	  measured	  using	  the	  HEK-­‐Blue-­‐4	  reporter	  cell	  line	  and	  
compared	  with	  E.	  coli	  K12	  LPS	  according	  to	  manufacturer	  instructions	  (HEK	  BlueTM	  LPS	  
Detection	  Kit,	  InvivoGen,	  USA).	  
	  
4.1.3.	  β-­‐galactosidase	  (β-­‐Gal)	  
For	  all	  immunization	  studies,	  β-­‐Gal	  (Roche,	  Germany)	  was	  dissolved	  in	  sterile	  water	  (5	  
mg/ml)	  and	  used	  as	  a	  model	  antigen.	  As	  described	  above,	  prepared	  β-­‐Gal	  used	  in	  the	  
studies	  was	  initially	  tested	  in	  a	  HEK-­‐Blue-­‐4	  reporter	  line	  and	  compared	  with	  E.	  coli	  K12	  LPS	  
to	  rule	  of	  the	  possibility	  of	  LPS	  contamination	  (HEK	  BlueTM	  LPS	  Detection	  Kit,	  InvivoGen,	  
USA).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
†	  This	  set	  of	  experiments	  was	  carried	  out	  at	  the	  Helmholtz	  Centre	  for	  Infection	  Research,	  
Braunschweig,	  Germany	  from	  May	  2011	  to	  August	  2011	  under	  the	  supervision	  of	  Thomas	  
Ebensen	  and	  Carlos	  Guzman	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4.1.4.	  Immunization	  protocols	  
Female	  BALB/c	  mice	  were	  immunized	  intranasally	  (i.n.)	  or	  sublingually	  (s.l.)	  on	  days	  0,	  14	  
and	  28	  with	  0.9%	  NaCl	  (negative	  control),	  30	  μg	  of	  β-­‐Gal,	  or	  30	  μg	  of	  β-­‐Gal	  co-­‐administered	  
with	  10	  μg	  of	  c-­‐di-­‐AMP	  (n=5,	  per	  group).	  Vaccines	  were	  formulated	  in	  0.9%	  NaCl	  and	  
prepared	  30	  minutes	  prior	  to	  immunization.	  For	  intranasal	  immunization,	  mice	  were	  
lightly	  anesthetized	  (30-­‐45	  seconds)	  by	  inhalation	  of	  Isoflurane®	  then	  given	  a	  20	  μl	  dose	  of	  
vaccine	  administered	  drop-­‐wise	  to	  the	  nostrils.	  For	  sublingual	  immunization,	  mice	  were	  
fully	  anesthetized	  (30-­‐40	  minutes)	  by	  intraperitoneal	  injection	  of	  Ketamin	  with	  Rompun	  
and	  given	  an	  8	  μl	  dose	  of	  vaccine	  administered	  under	  the	  tongue.	  To	  ensure	  the	  dose	  was	  
given	  sublingually	  and	  not	  orally,	  mice	  were	  fixed	  in	  a	  vertical	  position	  during	  
immunization	  and	  returned	  to	  their	  cages	  in	  a	  sitting	  position	  with	  their	  head	  lying	  on	  their	  
stomach	  until	  anesthesia	  subsided.	  
	  
4.1.5.	  Sample	  collection	  
Blood	  was	  drawn	  from	  all	  animals	  (through	  retro-­‐orbital	  plexus)	  by	  on	  days	  −1,	  13,	  27	  and	  
42.	  Blood	  samples	  were	  centrifuged	  (10	  min	  at	  3000	  g)	  to	  remove	  red	  blood	  cells	  and	  the	  
sera	  were	  stored	  at	  −20	  °C	  further	  until	  analysis.	  Mice	  were	  sacrificed	  on	  day	  42	  and	  nasal	  
(NL)	  and	  lung	  lavages	  (LL)	  were	  collected	  by	  flushing	  the	  organs	  with	  ice-­‐cold	  PBS	  
supplemented	  with	  50	  mM	  EDTA,	  0.1%	  bovine	  serum	  albumin,	  and	  10	  mM	  phenyl-­‐
methane-­‐sulfonylfluoride	  (PMSF).	  	  
	  
4.1.6.	  Detection	  of	  β-­‐Gal-­‐specific	  IgG,	  IgG1,	  IgG2a,	  and	  IgG2b	  in	  serum	  
	   17	  
Titers of antigen-specific IgG and isotypes (IgG1, IgG2a, IgG2b) to β-Gal were measured in 
serum by an enzyme-linked immunosorbent assay (ELISA) using	  microtiter	  plates	  (Microlon®	  
600	  High	  Binding)	  coated	  overnight	  at	  4	  °C	  with	  100	  μl/well	  of	  β-­‐Gal	  (2	  μg/ml	  in	  0.05	  M	  
carbonate	  buffer,	  pH	  9.6).	  Following	  overnight	  incubation	  plates	  were	  washed	  (PBS,	  0.1%	  
Tween	  20)	  using	  an	  automated	  plate	  washer	  (ELx	  405,	  Bio-­‐Tek)	  on	  a	  6-­‐cycle	  setting	  and	  
blocked	  (PBS,	  3%	  BSA)	  for	  1	  hour	  at	  37	  °C.	  Serial	  2-­‐fold	  dilutions	  (starting	  at	  1:1,000)	  of	  
sera	  in	  PBS,	  3%	  BSA	  were	  then	  added	  at	  100	  μl/well	  using	  an	  automated	  plate	  diluter	  
(Precision	  2000,	  Bio-­‐Tek),	  then	  incubated	  for	  2	  hours	  at	  37	  °C.	  After	  washing,	  secondary	  
antibodies	  were	  added	  in	  PBS,	  0.1%	  Tween	  20,	  1%	  BSA	  according	  to	  manufacture	  
recommendations:	  biotinylated	  γ-­‐chain-­‐specific	  goat	  anti-­‐mouse	  IgG	  (1:5,000)	  or	  
biotinylated	  goat	  anti-­‐mouse	  IgG1	  (1:5,000),	  IgG2a	  (1:10,000),	  or	  IgG2b	  (1:5,000).	  
Unbound	  detection	  antibody	  was	  removed	  with	  washing	  before	  the	  addition	  of	  100	  μl/well	  
of	  Streptavidin-­‐HRP	  solution	  (1:1000	  in	  PBS,	  0.1%	  Tween	  20,	  1%	  BSA)	  and	  incubation	  at	  
37	  °C	  for	  1	  hour.	  Following	  a	  final	  wash,	  reactions	  were	  developed	  using	  ABTS	  [2,20-­‐azino-­‐
bis	  (3-­‐	  ethylbenzthiazoline-­‐6-­‐sulfonic	  acid)]	  in	  0.1	  M	  citrate–phosphate	  buffer	  (pH	  4.35)	  
containing	  0.01%	  H2O2.	  Following	  a	  30	  minute	  incubation	  at	  room	  temperature,	  endpoint	  
titers	  were	  expressed	  as	  absolute	  values	  of	  the	  last	  dilution	  that	  gave	  an	  optical	  density	  at	  
405	  nm	  that	  was	  2-­‐fold	  greater	  than	  the	  negative	  control.	  
	  
4.1.7.	  Detection	  of	  β-­‐Gal-­‐specific	  IgA	  in	  nasal	  and	  lung	  lavage	  samples	  
The	  amount	  of	  antigen-­‐specific	  IgA to β-Gal per µg of total IgA was measured in	  nasal	  and	  
lung	  lavage	  samples	  by	  ELISA.	  Briefly,	  96-­‐well	  microtiter	  plates	  (Microlon®	  600	  High	  
Binding)	  were	  coated	  with	  100	  μl/well	  of	  β-­‐Gal	  (2	  μg/ml	  in	  0.05	  M	  carbonate	  buffer,	  pH	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9.6)	  and	  incubated	  overnight	  at	  4	  °C.	  For	  detection	  of	  total	  IgA	  and	  to	  generate	  a	  standard	  
curve,	  an	  additional	  plate	  was	  coated	  with	  100	  µl/well	  of	  anti-­‐mouse	  IgA	  (2	  μg/ml	  in	  0.05	  
M	  carbonate	  buffer,	  pH	  9.6)	  and	  incubated	  overnight	  at	  4	  °C.	  For	  antigen-­‐specific	  IgA,	  after	  
blocking	  (PBS,	  3%	  BSA)	  for	  1	  h	  at	  37	  °C,	  the	  plates	  were	  washed	  (PBS, 0.1% Tween 20) and	  
incubated	  with	  2-­‐fold	  serially	  diluted	  lavage	  samples	  (starting	  at	  1:4)	  for	  1	  hour	  at	  37	  °C.	  
For	  total	  IgA	  and	  standard,	  after	  blocking	  (PBS,	  3%	  BSA)	  for	  1	  h	  at	  37	  °C,	  the	  plates	  were	  
washed	  (PBS,	  0.1%	  Tween	  20)	  and	  incubated	  for	  one	  hour	  at	  37	  °C	  with	  either	  2-­‐fold	  
serially	  diluted	  lavage	  samples	  (starting	  at	  1:20)	  or	  standardized	  mouse	  IgA	  2-­‐fold	  serially	  
diluted	  in	  PBS,	  3%	  BSA	  (starting	  at	  2	  µg/ml).	  After	  washing,	  anti-­‐mouse	  IgA	  biotinylated	  
detection	  antibody	  was	  added	  to	  each	  well	  (1:5,000)	  and	  incubated	  for	  1	  hour	  at	  37	  °C.	  The	  
plates	  were	  then	  washed	  again	  and	  streptavidin-­‐HRP	  was	  added	  (1:1	  000)	  followed	  by	  a	  1	  
hour	  incubation	  at	  room	  temperature.	  Finally,	  plates	  were	  washed	  and	  reactions	  developed	  
using	  ABTS	  in	  0.1	  M	  citrate–phosphate	  buffer	  (pH	  4.35)	  containing	  0.01%	  H2O2.	  Following	  
a	  30	  minute	  incubation	  at	  room	  temperature,	  a	  standard	  curve	  was	  generated	  and	  endpoint	  
titers	  for	  total	  and	  antigen-­‐specific	  IgA	  were	  calculated.	  Values	  are	  expressed	  as	  antigen-­‐
specific	  titers	  per	  µg	  of	  total	  IgA.	  
	  
4.1.8.	  Measurement	  of	  cellular	  proliferation	  
Spleens	  and	  cervical	  lymph	  nodes	  of	  vaccinated	  mice	  were	  aseptically	  removed,	  single	  cell	  
suspensions	  were	  prepared	  and	  erythrocytes	  were	  lysed	  in	  ACK	  buffer	  (2	  minute	  
incubation).	  Cells	  were	  washed	  twice	  and	  adjusted	  to	  2	  x	  106	  cells/ml	  in	  RPMI	  complete	  
medium	  (RPMI,	  10%	  fetal	  bovine	  serum,	  100	  U/ml	  penicillin,	  100	  μg/ml	  streptomycin,	  1%	  
glucose).	  Cells	  were	  then	  seeded	  at	  200	  μl/well	  (5	  x	  105	  cells/well)	  in	  U-­‐bottomed	  96-­‐well	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microtitre	  plates	  and	  cultured	  in	  quadruplicate	  for	  72	  hours	  (5%	  CO2	  at	  37	  °C)	  in	  the	  
presence	  of	  different	  concentrations	  of	  β-­‐Gal	  (1,	  10,	  20,	  40	  μg/ml),	  Concanavalin	  A	  (5	  
μg/ml),	  or	  medium	  alone.22	  After	  72	  hours,	  1	  μCi	  of	  3H-­‐Thymidine	  in	  50	  μl	  of	  culture	  media	  
was	  added	  to	  each	  well.23	  Then	  after	  an	  additional	  18	  hour	  incubation,	  cells	  were	  harvested	  
on	  Filtermat	  A	  filters	  and	  the	  incorporation	  of	  thymidine	  into	  the	  DNA	  of	  proliferating	  cells	  
was	  determined	  using	  a	  scintillation	  counter	  (Wallac	  1450,	  Micro-­‐Trilux).	  The	  results	  are	  
expressed	  as	  a	  stimulation	  index	  (SI).	  
	  
Stimulation	  index	  (SI)	  =	  cpm	  with	  β-­‐Gal/cpm	  without	  β-­‐Gal	  
	  
4.1.9.	  Measurement	  of	  cytokine	  secreting	  cells	  by	  enzyme-­‐linked	  immune	  spot	  technique	  
(ELISPOT)	  
	  
To	  determine	  of	  the	  amount	  of	  cytokine	  secreting	  cells	  in	  the	  spleens	  and	  cervical	  lymph	  
nodes	  of	  vaccinated	  animals	  murine	  IFN-­‐γ,	  IL-­‐2,	  IL-­‐4	  and	  IL-­‐17	  ELISpot	  kits	  (BD	  
Pharmingen,	  USA)	  were	  used	  according	  to	  manufacturer	  instructions.	  Multiscreen	  plates	  
(Nunc-­‐Immuno	  MaxiSorp)	  were	  coated	  with	  100	  μl/well	  of	  capture	  antibody	  in	  PBS	  and	  
incubated	  overnight	  at	  4	  °C.	  Plates	  were	  then	  washed	  and	  blocked	  with	  RPMI	  complete	  
medium	  for	  2	  hours	  at	  room	  temperature	  (200	  μl/well).	  After	  washing	  again,	  spleen	  or	  
cervical	  lymph	  node	  cells,	  prepared	  as	  described	  above,	  were	  added	  in	  RPMI	  complete	  
medium	  (1	  x	  106	  cells/well)	  and	  incubated	  (37	  °C	  in	  5%	  CO2)	  for	  24	  hours	  (IFN-­‐γ)	  or	  48	  
hours	  (IL-­‐2,	  IL-­‐4,	  IL-­‐17)	  in	  the	  presence	  or	  absence	  of	  β-­‐Gal	  (5	  μg/ml).	  All	  final	  steps	  were	  
carried	  out	  according	  to	  manufacturer	  recommendations.	  Briefly,	  cells	  were	  removed	  and	  
detection	  antibodies	  (2	  hours	  at	  room	  temperature),	  avidin-­‐HRP	  (1	  hour	  at	  room	  
temperature),	  and	  substrates	  were	  added	  to	  plates,	  with	  washing	  following	  all	  steps.	  After	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allowing	  plates	  to	  air-­‐dry	  overnight,	  colored	  spots	  were	  counted	  with	  an	  ELISpot	  reader	  
(C.T.L.)	  and	  analyzed	  using	  the	  ImmunoSpot	  image	  analyzer	  (software	  v3.2).	  Each	  spot	  
detected	  represented	  a	  distinct	  cytokine-­‐secreting	  cell.	  
	  
4.1.10.	  Measurement	  of	  cytokine	  secretion	  by	  cytometric	  bead	  array	  
Flow	  cytometry	  was	  used	  to	  quantify	  the	  amount	  of	  cytokines	  and	  chemokines	  secreted	  by	  
immune	  cells.	  Spleen	  cells	  from	  vaccinated	  animals	  were	  seeded	  in	  96-­‐well	  flat-­‐bottomed	  
plates	  (5	  x	  105	  cells/well)	  and	  stimulated	  with	  different	  concentrations	  of	  β-­‐Gal	  (0,	  5,	  10,	  
20,	  40	  μg/ml)	  in	  RPMI	  complete	  media	  and	  incubated	  at	  37	  °C	  in	  37%	  CO2.	  Supernatants	  
were	  then	  collected	  after	  48,	  72,	  and	  96	  hours	  and	  stored	  at	  −80 °C	  until	  processing.	  The	  
amounts	  of	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐1α,	  IL-­‐2,	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐10,	  IL-­‐13,	  IL-­‐17,	  IL-­‐21,	  IL-­‐22,	  and	  
IL-­‐27	  were	  determined	  using	  a	  Mouse	  Th1/Th2/Th17/Th22	  13plex	  FlowCytomix	  cytokine	  
array	  according	  to	  the	  manufacturer’s	  instructions	  (eBioscience®).	  Supplied	  standards	  
were	  used	  to	  generate	  standard	  curves,	  and	  samples	  were	  analyzed	  by	  flow	  cytometry	  
(BD™	  LSR	  II	  Flow	  Cytometer).	  
	  
4.1.11.	  Statistical	  analysis	  of	  data	  
Data	  are	  expressed	  as	  means	  ±	  standard	  errors.	  For	  multiple	  group	  comparisons,	  one-­‐way	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4.2.	  Results	  
4.2.1.	  C-­‐di-­‐AMP	  and	  β-­‐Gal	  were	  LPS-­‐negative	  
To	  determine	  if	  potential	  LPS	  contamination	  could	  contribute	  to	  stimulation	  of	  TLR-­‐4,	  β-­‐Gal	  
and	  c-­‐di-­‐AMP	  were	  first	  tested	  in	  a	  HEK-­‐Blue-­‐4	  cell	  line.	  Using	  this	  cell	  line	  it	  was	  
confirmed	  that	  both	  c-­‐di-­‐AMP	  and	  β-­‐Gal	  tested	  negative	  for	  LPS,	  showing	  similar	  responses	  





Figure	  1.	  HEK-­‐Blue-­‐4	  cells	  were	  stimulated	  with	  0.9%	  NaCl	  (negative	  control),	  β-­‐Gal	  (150	  
μg/ml),	  c-­‐di-­‐AMP	  (10	  μg/ml),	  or	  E.	  coli	  K12	  LPS	  (10	  μg/ml)	  (positive	  control).	  After	  a	  20	  
hour	  incubation	  in	  HEK-­‐Blue	  Detection	  Media	  at	  37	  °C	  in	  5%	  CO2,	  NF-­‐κβ-­‐induced	  secreted	  
embryonic	  alkaline	  phosphatase	  (SEAP)	  activity	  was	  assessed	  by	  reading	  the	  optical	  
density	  at	  650	  nm.	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4.2.2.	  Induction	  of	  strong	  humoral	  immune	  responses	  at	  systemic	  and	  mucosal	  levels	  after	  
both	  intranasal	  and	  sublingual	  immunization	  using	  c-­‐di-­‐AMP	  as	  a	  mucosal	  adjuvant	  
	  
The	  ability	  of	  c-­‐di-­‐AMP	  to	  act	  as	  a	  mucosal	  adjuvant	  was	  analyzed	  in	  vivo	  by	  immunizing	  
BALB/c	  mice	  with	  the	  model	  antigen	  β-­‐Gal	  (30	  μg/dose)	  alone	  or	  co-­‐administered	  with	  c-­‐di	  
AMP	  (10	  μg/dose)	  by	  the	  intranasal	  and	  sublingual	  routes	  (n=5,	  per	  group),	  as	  described	  in	  
Methods.	  In	  comparison	  to	  animals	  vaccinated	  with	  β-­‐Gal	  alone,	  the	  use	  of	  c-­‐di-­‐AMP	  
significantly	  increased	  β-­‐Gal-­‐specific	  IgG	  titers	  following	  the	  first	  boost	  in	  both	  the	  
intranasal	  and	  sublingual	  groups	  (Fig.	  1).	  Fourteen	  days	  after	  the	  final	  immunization	  
animals	  vaccinated	  intranasally	  with	  β-­‐Gal	  co-­‐administered	  with	  c-­‐di-­‐AMP	  showed	  a	  2.25-­‐
fold	  (p-­‐value	  <0.01)	  increase	  in	  β-­‐Gal-­‐specific	  IgG	  responses,	  as	  compared	  to	  the	  sublingual	  
route	  (Fig.	  2).	  
The	  stimulation	  of	  mucosal	  immune	  responses	  by	  c-­‐di-­‐AMP	  was	  evaluated	  by	  
measuring	  β-­‐Gal-­‐specific	  IgA	  in	  nasal	  lavage	  (NL)	  and	  lung	  lavage	  (LL)	  samples	  taken	  from	  
vaccinated	  animals.	  Compared	  to	  animals	  vaccinated	  with	  β-­‐Gal	  alone,	  the	  use	  of	  c-­‐di-­‐AMP	  
enhanced	  antigen-­‐specific	  IgA	  titers	  in	  both	  mucosal	  territories,	  with	  similar	  responses	  
observed	  between	  intranasal	  and	  sublingual	  groups	  receiving	  β-­‐Gal	  with	  c-­‐di-­‐AMP	  (Fig.	  3).	  	  
	  
4.2.3.	  c-­‐di-­‐AMP	  stimulates	  β-­‐Gal-­‐specific	  cellular	  immune	  responses	  after	  both	  intranasal	  and	  
sublingual	  immunization	  
	  
Lymphoproliferative	  assays	  were	  carried	  out	  to	  evaluate	  the	  capacity	  of	  c-­‐di-­‐AMP	  to	  induce	  
cellular	  immune	  responses	  through	  intranasal	  and	  sublingual	  vaccination.	  Spleen	  cells	  or	  
cervical	  lymph	  node	  cells	  isolated	  14	  days	  after	  the	  final	  immunization	  were	  stimulated	  in	  
vitro	  with	  β-­‐Gal.	  The	  strongest	  proliferative	  responses	  were	  observed	  in	  cells	  from	  mice	  
receiving	  β-­‐Gal	  in	  combination	  with	  c-­‐di-­‐AMP.	  In	  contrast,	  no	  responses	  were	  observed	  in	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spleen	  cells	  or	  cervical	  lymph	  node	  cells	  from	  mice	  immunized	  with	  the	  β-­‐Gal	  alone.	  
Similarly	  strong	  proliferative	  responses	  were	  observed	  in	  the	  intranasal	  and	  sublingual	  
animals	  that	  received	  β-­‐Gal	  co-­‐administered	  with	  c-­‐di-­‐AMP	  (Fig.	  4A-­‐D).	  
	  
4.2.4.	  c-­‐di-­‐AMP	  stimulates	  a	  predominately	  Th1/Th17	  T	  cell	  response	  through	  both	  sublingual	  
and	  intranasal	  vaccination	  	  
	  
To	  assess	  the	  effect	  of	  c-­‐di-­‐AMP	  on	  T	  helper	  responses,	  β-­‐Gal-­‐specific	  serum	  IgG	  isotypes	  
were	  first	  analyzed.	  In	  comparison	  to	  mice	  vaccinated	  with	  β-­‐Gal	  alone,	  intranasal	  
immunization	  with	  β-­‐Gal	  in	  combination	  with	  c-­‐di-­‐AMP	  significantly	  enhanced	  expression	  
of	  IgG1,	  IgG2a,	  and	  IgG2b.	  For	  mice	  immunized	  sublingually,	  c-­‐di-­‐AMP	  significantly	  
enhanced	  expression	  of	  IgG2a	  and	  IgG2b,	  but	  not	  IgG1.	  In	  comparison	  to	  sublingual	  
immunization,	  intranasal	  vaccination	  with	  c-­‐di-­‐AMP	  resulted	  in	  a	  7-­‐fold	  (p-­‐value	  <0.05)	  
and	  2.5-­‐fold	  (p-­‐value	  <0.05)	  enhancement	  of	  IgG1	  and	  IgG2a,	  respectively.	  Taken	  together,	  
these	  data	  suggest	  c-­‐di-­‐AMP	  stimulates	  a	  predominantly	  Th1	  T	  helper	  response,	  with	  
overall	  enhancement	  through	  intranasal	  immunization	  (Fig.	  5).	  
ELISpot	  was	  utilized	  to	  further	  investigate	  the	  effect	  of	  c-­‐di-­‐AMP	  on	  T	  helper	  
responses	  by	  identifying	  populations	  of	  β-­‐Gal-­‐specific	  IFN-­‐γ,	  IL-­‐2,	  IL-­‐4	  and	  IL-­‐17	  secreting	  
cells.	  When	  stimulated	  with	  β-­‐Gal	  in	  vitro,	  splenocytes	  from	  mice	  immunized	  intranasally	  
with	  β-­‐Gal	  and	  c-­‐di-­‐AMP	  exhibited	  a	  largely	  Th1/Th17	  phenotype	  based	  on	  their	  cytokine	  
profile	  (IFN-­‐γ+++,	  IL-­‐2+,	  IL-­‐4+,	  IL-­‐17+++).	  Similarly,	  sublingual	  immunization	  resulted	  in	  a	  
strongly	  Th1/Th17	  profile	  (IFN-­‐γ+++,	  IL-­‐2++,	  IL-­‐4+,	  IL-­‐17+++).	  	  No	  statistical	  difference	  was	  
observed	  between	  intranasal	  and	  sublingual	  animals	  that	  received	  β-­‐Gal	  co-­‐administered	  
with	  c-­‐di-­‐AMP	  (Fig.	  6).	  When	  cervical	  lymph	  node	  cells	  from	  mice	  immunized	  intranasally	  
were	  analyzed	  their	  profile	  was	  almost	  exclusively	  Th1/Th17	  (IFN-­‐γ++,	  IL-­‐2+,	  IL-­‐4-­‐,	  IL-­‐17++);	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and	  a	  similar	  profile	  was	  observed	  in	  mice	  immunized	  sublingually	  (IFN-­‐γ+,	  IL-­‐2+,	  IL-­‐4-­‐,	  IL-­‐
17++).	  Here,	  however,	  intranasal	  immunization	  enhanced	  IFN-­‐γ	  secretion	  in	  the	  population	  
3-­‐fold	  (p-­‐value	  <0.05)	  in	  comparison	  to	  sublingual	  immunization,	  when	  β-­‐Gal	  was	  co-­‐














Figure	  2.	  Kinetic	  analysis	  of	  anti-­‐β-­‐Gal	  IgG	  responses	  in	  sera	  of	  BALB/c	  mice	  immunized	  on	  days	  
0,	  14	  and	  28	  with	  0.9%	  NaCl	  (control),	  30	  ug/dose	  of	  β-­‐Gal	  alone,	  or	  β-­‐Gal	  co-­‐administered	  with	  
10	  ug/dose	  of	  c-­‐di-­‐AMP	  by	  the	  sublingual	  and	  intranasal	  routes	  (n	  =	  5,	  per	  group).	  Sera	  was	  
collected	  2-­‐3	  days	  prior	  to	  each	  immunization	  and	  fourteen	  days	  after	  the	  final	  immunization	  and	  
analyzed	  by	  ELISA.	  Significant	  with	  respect	  to	  mice	  receiving	  antigen	  alone	  	  (*,	  p	  <	  0.01).	  
Significant	  with	  respect	  to	  mice	  receiving	  the	  antigen	  co-­‐administered	  with	  c-­‐di-­‐AMP	  by	  the	  s.l.	  












	   	  
Figure	  3.	  Analysis	  of	  anti-­‐β-­‐Gal	  IgA	  responses	  in	  lavage	  samples	  of	  BALB/c	  mice	  immunized	  on	  
days	  0,	  14	  and	  28	  with	  0.9%	  NaCl	  (control),	  30	  ug/dose	  of	  β-­‐Gal	  alone,	  or	  β-­‐Gal	  co-­‐administered	  
with	  10	  ug/dose	  of	  c-­‐di-­‐AMP	  by	  the	  sublingual	  and	  intranasal	  routes	  (n	  =	  5,	  per	  group).	  Lavage	  
samples	  were	  collected	  on	  day	  42	  and	  analyzed	  by	  ELISA.	  Significant	  with	  respect	  to	  mice	  
receiving	  antigen	  alone	  	  (**,	  p	  <	  0.001).	  
	  






	   	  
Figure	  4.	  Analysis	  of	  cell	  proliferation.	  Spleen	  cells	  (5	  x	  105)	  or	  cervical	  lymph	  node	  cells	  (5	  x	  105)	  from	  
vaccinated	  animals	  were	  restimulated	  with	  different	  concentrations	  of	  β-­‐Gal	  (0,	  1,	  10,	  20,	  40	  μg/ml)	  for	  96	  
hours.	  Cellular	  proliferation	  was	  then	  assessed	  by	  determination	  of	  [3H]	  thymidine	  incorporated	  into	  the	  DNA	  
of	  replicating	  cells.	  (A)	  Results	  from	  spleen	  cells	  expressed	  as	  a	  stimulation	  index	  (SI).	  (B)	  Results	  from	  
cervical	  lymph	  node	  cells	  expressed	  as	  a	  stimulation	  index	  (SI).	  All	  results	  are	  the	  mean	  value	  of	  
quadruplicates.	  Significant	  with	  respect	  to	  mice	  receiving	  antigen	  alone	  (*,	  p	  <	  0.01).	  	  
	  
	  










Figure	  5.	  Analysis	  of	  β-­‐Gal-­‐specific	  IgG	  subclasses	  (IgG1,	  IgG2a,	  IgG2b)	  in	  sera	  of	  immunized	  
BALB/c	  mice	  at	  day	  42	  (n	  =	  5,	  per	  group).	  Fourteen	  days	  after	  the	  final	  immunization	  sera	  
samples	  of	  immunized	  mice	  were	  analyzed	  by	  ELISA.	  Significant	  with	  respect	  to	  mice	  
receiving	  antigen	  alone	  (*,	  p	  <	  0.01).	  Significant	  with	  respect	  to	  mice	  receiving	  the	  antigen	  co-­‐
administered	  with	  c-­‐di-­‐AMP	  by	  the	  s.l.	  route	  (o,	  p	  <	  0.01).	  	  
	  
	  
























Figure	  6.	  Detection	  of	  cytokine	  secreting	  cells.	  Cervical	  lymph	  node	  cells	  (1	  x	  106)	  recovered	  from	  
vaccinated	  mice	  were	  incubated	  for	  24	  or	  48	  h	  in	  the	  presence	  of	  B-­‐Gal	  protein,	  the	  number	  of	  cytokine	  
secreting	  cells	  was	  then	  determined	  by	  ELISPOT.	  Results	  are	  presented	  as	  spot	  forming	  units	  per	  1	  x	  106	  
cells,	  which	  were	  subtracted	  from	  the	  values	  obtained	  from	  non-­‐stimulated	  cells.	  Significant	  with	  
respect	  to	  mice	  receiving	  antigen	  alone	  (*,	  p	  <	  0.01).	  Significant	  with	  respect	  to	  mice	  receiving	  the	  


























Figure	  7.	  Detection	  of	  cytokine	  secreting	  cells.	  Spleen	  cells	  (1	  x	  106)	  recovered	  from	  vaccinated	  mice	  were	  
incubated	  for	  24	  or	  48	  h	  in	  the	  presence	  of	  β-­‐Gal	  protein,	  the	  number	  of	  cytokine	  secreting	  cells	  was	  then	  
determined	  by	  ELISPOT.	  Results	  are	  presented	  as	  spot	  forming	  units	  per	  1	  x	  106	  cells,	  which	  were	  
subtracted	  from	  the	  values	  obtained	  from	  non-­‐stimulated	  cells.	  Significant	  with	  respect	  to	  mice	  receiving	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4.2.5	  cytokine	  secretion	  	  
	  
To	  further	  investigate	  the	  effect	  of	  c-­‐di-­‐AMP	  on	  cytokine	  production,	  spleen	  cells	  from	  
vaccinated	  animals	  were	  stimulated	  in	  vitro	  with	  β-­‐Gal	  and	  supernatants	  were	  evaluated	  
over	  time	  using	  a	  Mouse	  Th1/Th2/Th17/Th22	  13plex	  FlowCytomix	  Multiplex	  
	  (eBioscience®).	  Enhanced	  secretion	  of	  IFN-­‐γ,	  TNF-­‐α,	  IL-­‐2,	  IL-­‐13,	  IL-­‐17,	  IL-­‐22,	  and	  IL-­‐27	  
was	  observed	  in	  cells	  from	  c-­‐di-­‐AMP	  vaccinated	  mice	  with	  respect	  to	  supernatants	  from	  
cells	  of	  animals	  immunized	  with	  β-­‐Gal	  alone.	  Overall,	  trends	  were	  very	  similar	  between	  
intranasal	  and	  sublingual	  groups;	  with	  one	  noted	  exception	  being	  IL-­‐27	  was	  only	  observed	  
in	  the	  intranasal	  group	  (Fig.	  8-­‐9).	  	  
Looking	  at	  concentrations	  across	  time,	  some	  general	  trends	  were	  observed.	  For	  
example,	  IL-­‐2	  and	  TNF-­‐α	  were	  strongly	  produced	  early	  after	  stimulation	  (48	  hours)	  then	  
decreased	  thereafter.	  Conversely,	  concentrations	  of	  IL-­‐22	  gradually	  increased	  across	  time;	  
and	  still	  further,	  cytokines	  such	  IFN-­‐γ	  and	  IL-­‐13,	  while	  largely	  undetectable	  at	  48	  hours,	  
stabilized	  at	  a	  high	  concentration	  by	  72	  and	  96	  hours	  post-­‐stimulation.	  Overall,	  cytokine	  
profiles	  indicate	  a	  mixed,	  but	  largely	  Th1/Th17	  T	  cell	  response,	  as	  evidenced	  by	  high	  
concentrations	  of	  IFN-­‐γ	  (Th1),	  IL-­‐22	  (Th17),	  and	  IL-­‐17	  (Th17);	  and	  the	  absence	  of	  Th2	  
cytokines,	  such	  as	  IL-­‐4	  and	  IL-­‐5.	  The	  exception	  to	  this	  was	  IL-­‐13	  (Th2),	  which	  was	  strongly	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Figure	  8.	  Analysis	  of	  cytokines	  secreted	  by	  antigen-­‐restimulated	  splenocytes	  of	  mice	  
immunized	  by	  the	  intranasal	  route	  with	  (A)	  β-­‐Gal	  or	  (B)	  β-­‐Gal	  co-­‐administered	  with	  c-­‐
di-­‐AMP	  (n	  =	  5).	  Cells	  (5	  x	  105)	  were	  restimulated	  in	  quadruplicates	  with	  different	  
concentrations	  of	  β-­‐Gal	  for	  48h,	  72h,	  and	  96	  h.	  At	  the	  end	  of	  each	  time-­‐point,	  
supernatants	  were	  pooled	  from	  the	  quadruplicates	  and	  the	  secreted	  cytokines	  (IL-­‐13,	  
IL-­‐1alpha,	  IL-­‐22,	  IL-­‐2,	  IL-­‐5,	  IL-­‐21,	  IL-­‐6,	  IL-­‐10,	  IL-­‐27,	  IFN-­‐gamma,	  TNF-­‐alpha,	  IL-­‐4,	  IL-­‐17)	  
were	  analyzed	  by	  a	  Th1/Th2/Th17/Th22	  Flowcytomix	  array.	  Results	  are	  shown	  from	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Figure	  9.	  Analysis	  of	  cytokines	  secreted	  by	  antigen-­‐restimulated	  splenocytes	  of	  mice	  
immunized	  by	  the	  sublingual	  route	  with	  (A)	  B-­‐Gal	  	  or	  (B)	  β-­‐Gal	  co-­‐administered	  with	  c-­‐
di-­‐AMP	  (n	  =	  5).	  Cells	  (5	  x	  105)	  were	  restimulated	  in	  quadruplicates	  with	  different	  
concentrations	  of	  B-­‐Gal	  for	  48h,	  72h,	  and	  96	  h.	  At	  the	  end	  of	  each	  time-­‐point,	  
supernatants	  were	  pooled	  from	  the	  quadruplicates	  and	  the	  secreted	  cytokines	  (IL-­‐13,	  
IL-­‐1alpha,	  IL-­‐22,	  IL-­‐2,	  IL-­‐5,	  IL-­‐21,	  IL-­‐6,	  IL-­‐10,	  IL-­‐27,	  IFN-­‐gamma,	  TNF-­‐alpha,	  IL-­‐4,	  IL-­‐
17)	  were	  analyzed	  by	  a	  Th1/Th2/Th17/Th22	  Flowcytomix	  array.	  Results	  are	  shown	  




















	   	  
Table	  2.	  Overview	  of	  cytokines	  secreted	  by	  antigen-­‐restimulated	  splenocytes	  of	  mice	  immunized	  by	  the	  
sublingual	  and	  intranasal	  routes	  with	  B-­‐Gal	  (30	  ug/dose)	  co-­‐administered	  with	  c-­‐di-­‐AMP	  (10	  ug/dose)	  (n	  
=	  5).	  Cells	  (5	  x	  105)	  were	  restimulated	  in	  quadruplicates	  with	  different	  concentrations	  of	  B-­‐Gal	  for	  48h,	  
72h,	  and	  96	  h.	  At	  the	  end	  of	  each	  time-­‐point,	  supernatants	  were	  pooled	  from	  the	  quadruplicates	  and	  the	  
secreted	  cytokines	  were	  analyzed	  by	  a	  Th1/Th2/Th17/Th22	  Flowcytomix	  array.	  Results	  are	  shown	  from	  
splenocytes	  restimulated	  with	  40	  ug/ml	  of	  B-­‐Gal.	  Blue	  indicates	  Th1	  cytokines,	  red	  Th2	  cytokines,	  and	  
green	  a	  Th17	  cytokine.	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5.	  Intranasal	  immunization	  with	  Ancylostoma	  ceylanicum	  excretory-­‐secretory	  (ES)	  




5.1.1.	  Parasites	  and	  hosts	  
The	  Ancylostoma	  ceylanicum	  life	  cycle	  was	  maintained	  in	  3	  week-­‐old	  Syrian	  golden	  
hamsters	  of	  the	  HsdHan:	  AURA	  outbred	  strain	  (Harlan,	  Indianapolis	  IN),	  as	  previously	  
described.24	  Immunization	  and	  challenge	  studies	  were	  also	  conducted	  in	  Syrian	  golden	  
hamsters.	  Animals	  were	  housed	  at	  the	  Yale	  School	  of	  Public	  Health,	  and	  all	  experiments	  
were	  performed	  with	  the	  prior	  approval	  of	  the	  Yale	  Animal	  Care	  and	  Use	  Committee.	  
	  
5.1.2.	  Bis-­‐(3’,5’)-­‐cyclic	  dimeric	  adenosine	  monophosphate	  (c-­‐di-­‐AMP)	  
As	  described	  previously,	  c-­‐di-­‐AMP	  (LPS	  negative)	  was	  synthesized	  by	  cyclization	  and	  
purified	  by	  reversed	  phase	  HPLC	  (100).	  The	  lyophilized	  compound	  was	  stored	  at	  −20	  °C	  
until	  use	  when	  it	  was	  resuspended	  in	  sterile	  water	  for	  the	  immunization	  studies.	  	  
	  
5.1.3.	  A.	  ceylanicum	  excretory-­‐secretory	  (ES)	  proteins	  
ES	  products	  were	  prepared	  as	  previously	  described.25	  Briefly,	  live	  adult	  A.	  ceylanicum	  
hookworms	  were	  rinsed	  and	  incubated	  in	  sterile	  PBS	  (10	  worms	  per	  ml)	  for	  6	  h	  at	  37°C.	  
The	  worms	  were	  then	  removed,	  and	  the	  raw	  ES	  products	  were	  centrifuged	  (15	  mins	  at	  3	  
300	  g)	  before	  being	  passed	  through	  a	  0.45-­‐µm	  filter	  to	  remove	  insoluble	  particles.	  The	  
flow-­‐through	  was	  then	  concentrated	  using	  a	  centrifugal	  concentrator	  with	  a	  5-­‐kDa	  
molecular	  weight	  cut-­‐off	  (Millipore	  Corp.,	  Bedford,	  MA),	  and	  the	  final	  concentration	  of	  ES	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
†	  This	  set	  of	  experiments	  was	  carried	  out	  at	  the	  Yale	  School	  of	  Public	  Health,	  New	  Haven,	  CT	  
from	  November	  2011	  to	  April	  2012	  under	  the	  supervision	  of	  Michael	  Cappello	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protein	  was	  determined	  using	  the	  BCA	  system	  (Pierce	  Chemical	  Co.,	  Rockford,	  IL)	  with	  a	  
bovine	  serum	  albumin	  standard	  curve.	  Aliquots	  of	  concentrated	  ES	  were	  stored	  at	  –80°C	  
until	  use.	  
	  
5.1.4.	  Immunization	  and	  challenge	  infection	  of	  hamsters	  
Male	  3-­‐week	  old	  Syrian	  golden	  hamsters	  were	  immunized	  intranasally	  (i.n.)	  on	  days	  0,	  14,	  
and	  28	  with	  sterile	  PBS	  (buffer	  control),	  15	  μg	  of	  c-­‐di-­‐AMP,	  100	  μg	  of	  ES,	  or	  100	  μg	  of	  ES	  co-­‐
administered	  with	  15	  μg	  of	  c-­‐di-­‐AMP	  (n=5,	  per	  group).	  Vaccines	  were	  formulated	  in	  sterile	  
PBS	  and	  prepared	  30	  minutes	  prior	  to	  immunization.	  During	  intranasal	  immunization,	  mice	  
were	  lightly	  anesthetized	  (10-­‐25	  seconds)	  by	  inhalation	  of	  CO2	  then	  given	  an	  80	  μl	  dose	  of	  
vaccine	  administered	  drop-­‐wise	  to	  the	  nostrils.	  One	  week	  after	  the	  final	  immunization	  (day	  
35)	  immunized	  groups	  were	  infected	  by	  oral	  gavage	  with	  100	  third-­‐stage	  larvae	  (L3)	  of	  A.	  
ceylanicum.	  An	  additional	  group	  of	  hamsters	  (n=5)	  was	  left	  untreated	  and	  uninfected	  that	  
served	  as	  a	  negative	  control	  of	  hookworm	  pathogenesis.	  
	  
5.1.5.	  Sample	  collection	  	  
Blood	  was	  drawn	  from	  all	  animals	  by	  retro	  orbital	  puncture	  and	  collected	  in	  heparinized	  
capillary	  tubes	  (Fisher	  Scientific)	  1	  day	  before	  all	  immunizations	  and	  twice	  per	  week	  
throughout	  the	  challenge	  infection	  period.	  For	  analysis	  of	  antigen-­‐specific	  IgG	  responses,	  
samples	  were	  centrifuged	  (10	  minutes	  at	  3000	  g)	  to	  remove	  red	  blood	  cells	  and	  the	  sera	  
stored	  at	  -­‐80°C	  until	  further	  analysis.	  For	  measurement	  of	  hemoglobin	  levels,	  blood	  was	  
assayed	  within	  4	  hours	  using	  a	  Total	  Hemoglobin	  assay	  kit	  (see	  below).	  At	  22	  days	  post-­‐
infection	  (dpi),	  all	  animals	  were	  euthanized	  and	  adult	  worms	  removed	  and	  counted.	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Intestinal	  flush	  and	  lung	  lavage	  were	  collected	  and	  feces	  removed	  from	  large	  intestines	  for	  
individual	  egg	  per	  gram	  counts,	  as	  described	  below.	  
For	  the	  analysis	  of	  mucosal	  antigen-­‐specific	  immunoglobulin	  A	  (IgA),	  lung	  lavage	  
(LL)	  and	  intestinal	  flush	  (IF)	  were	  performed.	  For	  lung	  lavage,	  a	  small	  incision	  was	  made	  in	  
the	  trachea	  and	  2	  ml	  of	  ice	  cold	  PBS	  was	  carefully	  injected	  into	  the	  lungs	  and	  aspirated	  
using	  a	  gavage	  needle	  (20	  Gauge	  x	  1.5”).	  To	  remove	  large	  debris,	  lavage	  samples	  were	  
centrifuged	  (15	  min	  at	  16	  000	  g	  [4°C])	  and	  the	  supernatants	  collected.	  For	  intestinal	  flush,	  
small	  intestines	  were	  excised	  from	  hamsters	  and	  flushed	  with	  10	  mL	  PBS	  using	  a	  syringe	  
and	  18	  gauge	  needle,	  manually	  extruding	  any	  remaining	  mucus.	  The	  raw	  flush	  was	  gently	  
agitated	  for	  1	  min,	  centrifuged	  (15	  min	  at	  16	  000	  g	  [4	  °C])	  and	  the	  supernatant	  passed	  
through	  a	  0.45-­‐µm	  syringe	  filter.	  For	  both	  lung	  lavage	  and	  intestinal	  flush,	  samples	  were	  
stored	  at	  -­‐80	  °C	  until	  further	  analysis.25	  In	  all	  cases,	  the	  expression	  of	  antigen-­‐specific	  IgA	  
antibodies	  was	  determined	  in	  individual	  animals.	  
Following	  intestinal	  flush,	  worm	  burdens	  for	  each	  animal	  were	  counted	  by	  
longitudinally	  dissecting	  intestines	  and	  repeatedly	  rinsing	  them	  with	  room	  temperature	  
PBS.	  This	  treatment	  caused	  most	  of	  the	  worms	  to	  detach	  from	  the	  mucosa,	  and	  the	  
remaining	  worms	  were	  then	  gently	  removed	  from	  the	  intestinal	  debris	  with	  fine-­‐tipped	  
forceps	  and	  the	  aid	  of	  a	  dissecting	  microscope.	  To	  calculate	  fecal	  egg	  excretion,	  large	  
intestines	  were	  excised	  from	  hamsters	  and	  feces	  manually	  extruded	  into	  collection	  tubes.	  
Fecal	  samples	  were	  stored	  a	  4	  °C,	  and	  eggs	  were	  counted	  within	  4	  days	  of	  collection	  (see	  
below).	  Worm	  burden	  and	  fecal	  egg	  counts	  were	  determined	  in	  individual	  animals.	  
	  
5.1.6.	  Measurement	  of	  blood	  hemoglobin	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Blood	  was	  drawn	  from	  all	  animals	  by	  retro	  orbital	  puncture	  and	  collected	  in	  heparinized	  
capillary	  tubes	  (Fisher	  Scientific)	  and	  assayed	  within	  4	  hours	  of	  collection.	  Hemoglobin	  
levels	  were	  measured	  using	  a	  Total	  Hemoglobin	  assay	  kit	  (Sigma),	  as	  previously	  
described.26	  Briefly,	  10	  μl	  of	  whole	  blood	  was	  mixed	  into	  2.5	  mL	  Drabkin’s	  solution	  and	  
incubated	  for	  15	  min	  at	  room	  temperature.	  Sample	  tubes	  were	  then	  vortexed,	  200	  μl	  were	  
transferred	  in	  duplicate	  wells	  to	  a	  microtiter	  plate,	  and	  samples,	  including	  a	  hemoglobin	  
standard	  curve	  prepared	  from	  kit	  reagents,	  were	  read	  at	  530	  nm	  in	  using	  a	  SpectraMax	  190	  
microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  
	  
5.1.7.	  Measurement	  of	  fecal	  egg	  counts	  
A	  modified	  McMaster	  technique	  was	  used	  to	  calculate	  fecal	  egg	  excretion.	  The	  McMaster	  
method	  was	  based	  on	  the	  modified	  McMaster	  described	  by	  the	  Ministry	  of	  Agriculture,	  
Fisheries,	  and	  Food	  (1986).27	  Briefly,	  1	  gram	  of	  feces	  was	  suspended	  in	  10	  ml	  of	  saturated	  
salt	  solution	  at	  room	  temperature.	  The	  suspension	  was	  then	  homogenized,	  and	  poured	  
through	  gauze	  to	  remove	  large	  debris.	  Then,	  0.5	  ml	  aliquots	  were	  added	  to	  each	  of	  the	  two	  
chambers	  of	  a	  McMaster	  slide	  (http://www.mcmaster.co.za),	  and	  both	  chambers	  were	  
examined	  under	  a	  light	  microscope	  using	  a	  100x	  magnification.	  The	  fecal	  egg	  counts	  were	  
obtained	  by	  multiplying	  the	  total	  number	  of	  eggs	  by	  33,	  and	  expressed	  as	  eggs	  per	  gram	  
(EPG).	  
	  
5.1.8.	  Detection	  of	  ES-­‐specific	  IgG	  in	  serum	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The	  amount	  of	  ES-­‐specific	  IgG	  in	  serum	  was	  measured	  by	  ELISA.	  Immulon-­‐2	  microtitre	  
plates	  (Dynex,	  Chantilly,	  VA)	  were	  coated	  with	  100	  µl/well	  of	  ES	  diluted	  to	  2	  µg/ml	  in	  
sterile	  PBS	  and	  incubated	  overnight	  at	  4	  °C.	  The	  following	  day,	  plates	  were	  washed	  (PBS,	  
0.05%	  Tween	  20)	  4	  times	  and	  blocked	  (PBS,	  1%	  Milk)	  for	  1	  h	  at	  room	  temperature	  (RT).	  
For	  pooled	  samples,	  after	  washing,	  serial	  2-­‐fold	  dilutions	  (starting	  at	  1:25)	  of	  sera	  in	  PBS,	  
0.05%	  Tween	  20,	  1%	  Milk	  were	  added	  at	  100	  μl/well,	  then	  incubated	  for	  2	  hours	  at	  37	  °C.	  
For	  individual	  samples,	  sera	  was	  diluted	  1:4	  in	  PBS,	  0.05%	  Tween,	  1%	  Milk	  then	  added	  to	  
plates	  in	  duplicate	  and	  incubated	  for	  2	  hours	  at	  37	  °C.	  After	  washing,	  100	  μl/well	  of	  HRP-­‐
conjugated	  goat	  anti-­‐hamster	  IgG	  were	  added	  in	  PBS,	  0.05%	  Tween	  20	  and	  incubated	  at	  37	  
°C	  for	  1	  hour.	  After	  another	  wash	  step,	  reactions	  developed	  with	  a	  30	  min	  incubation	  in	  
ABTS	  (1	  mg/mL	  ABTS	  in	  0.1	  molar	  citrate	  buffer,	  pH	  5.0,	  0·03%	  H2O2).	  For	  individual	  
samples,	  the	  mean	  optical	  density	  at	  405	  nm	  was	  reported	  after	  subtraction	  of	  background.	  
For	  pooled	  samples,	  antigen-­‐specific	  titers	  were	  calculated	  by	  interpolating	  the	  dilution	  
giving	  an	  optical	  density	  of	  0.2	  after	  subtraction	  of	  background.	  All	  values	  were	  reported	  
using	  a	  SpectraMax	  190	  microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA),	  and	  
normalized	  to	  a	  positive	  standard	  (serum	  from	  hamsters	  previously	  collected	  104	  days	  
post-­‐infection),	  which	  was	  included	  in	  each	  assay	  to	  control	  for	  day-­‐to-­‐day	  variation.	  
	  
5.1.9.	  Detection	  of	  ES-­‐specific	  IgA	  in	  intestinal	  flush	  and	  lung	  lavage	  samples	  
Similar	  to	  IgG,	  ELISA	  was	  used	  to	  measure	  the	  amount	  of	  ES-­‐specific	  IgA	  in	  intestinal	  flush	  
and	  lung	  lavage	  samples.	  Briefly,	  Immulon-­‐2	  microtitre	  plates	  (Dynex,	  Chantilly,	  VA)	  were	  
coated	  with	  100	  µl/well	  of	  ES	  diluted	  to	  2	  µg/ml	  in	  sterile	  PBS	  and	  incubated	  overnight	  at	  4	  
°C.	  After	  blocking	  (PBS,	  1%	  Milk),	  with	  wash	  steps	  (PBS,	  0.05%	  Tween	  20)	  before	  and	  after,	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100	  µl/well	  of	  intestinal	  flush	  or	  lung	  lavage	  samples	  diluted	  1:4	  in	  PBS,	  0.05%	  Tween,	  1%	  
Milk	  were	  added	  in	  duplicate	  and	  the	  plates	  incubated	  overnight	  at	  4	  °C.	  The	  following	  day,	  
plates	  were	  washed	  and	  100	  µl/well	  of	  biotinylated	  anti-­‐mouse	  IgA	  α-­‐chain	  (1:1	  000	  in	  
PBS,	  0.05%	  Tween,	  1%	  Milk)	  were	  added	  and	  plates	  incubated	  for	  2	  h	  at	  RT.	  After	  washing	  
again,	  streptavidin-­‐HRP	  solution	  (1:5000	  in	  PBS,	  0.05%	  Tween	  20)	  was	  added	  and	  plates	  
were	  incubated	  at	  37	  °C	  for	  1	  h.	  Finally,	  plates	  were	  washed	  and	  reactions	  developed	  using	  
ABTS	  (1	  mg/mL	  ABTS	  in	  0.1	  molar	  citrate	  buffer,	  pH	  5.0,	  0·03%	  H2O2).	  After	  30	  min	  
incubation	  at	  room	  temperature,	  the	  mean	  optical	  density	  at	  405	  nm	  was	  reported	  using	  a	  
SpectraMax	  190	  microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA)	  after	  subtraction	  of	  
background.	  
	  
5.1.10.	  Statistical	  analysis	  of	  data	  
Data	  are	  expressed	  as	  means	  ±	  standard	  errors.	  For	  multiple	  group	  comparisons,	  one-­‐way	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5.2.	  Results	  	  
5.2.1.	  Induction	  of	  humoral	  immune	  responses	  at	  systemic	  and	  mucosal	  levels	  following	  
intranasal	  immunization	  with	  non-­‐adjuvated	  ES	  	  	  	  	  
	  
To	  evaluate	  the	  efficacy	  of	  c-­‐di-­‐AMP	  as	  a	  mucosal	  adjuvant	  in	  formulation	  with	  hookworm	  
antigens,	  hamsters	  were	  immunized	  intranasally	  on	  days	  0,	  14,	  and	  28	  with	  PBS	  (control),	  
15	  µg/dose	  c-­‐di-­‐AMP	  (adjuvant),	  100	  µg/dose	  A.	  ceylanicum	  excretory-­‐secretory	  (ES)	  
proteins,	  or	  100	  µg/dose	  ES	  co-­‐administered	  with	  15	  µg/dose	  c-­‐di-­‐AMP.	  One	  week	  after	  the	  
last	  dose	  animals	  were	  infected	  with	  100	  third-­‐stage	  A.	  ceylanicum	  larvae	  (L3),	  as	  described	  
in	  Methods.	  	  
Although	  results	  are	  representative	  of	  pooled	  serum	  samples,	  ES-­‐specific	  IgG	  
responses	  were	  similar	  in	  ES	  and	  ES	  plus	  adjuvant	  treatment	  groups.	  In	  both	  ES	  groups	  
responses	  were	  similar	  following	  the	  second	  boost	  at	  day	  35	  when	  animals	  were	  
challenged;	  and	  although	  primary	  infection	  increased	  IgG	  responses	  in	  all	  animals,	  by	  22	  
days	  post-­‐infection	  (dpi)	  both	  ES	  groups	  showed	  enhanced	  ES-­‐specific	  IgG	  in	  comparison	  
to	  PBS	  and	  c-­‐di-­‐AMP	  treated	  groups	  (Fig.	  10).	  	  
The	  stimulation	  of	  mucosal	  immune	  responses	  by	  immunization	  and	  infection	  were	  
evaluated	  by	  measuring	  ES-­‐specific	  IgA	  in	  lung	  lavage	  (LL)	  and	  intestinal	  flush	  (IF)	  samples	  
taken	  from	  all	  animals	  22	  dpi.	  Here	  again,	  compared	  to	  animals	  vaccinated	  with	  ES	  alone,	  
the	  use	  of	  c-­‐di-­‐AMP	  did	  not	  enhance	  antigen-­‐specific	  IgA	  responses,	  with	  similar	  responses	  
observed	  between	  ES	  groups	  in	  both	  mucosal	  compartments.	  In	  the	  ES	  alone	  group,	  a	  
significant	  enhancement	  in	  ES-­‐specific	  IgA	  was	  observed	  in	  intestinal	  flush	  samples,	  as	  
compared	  to	  PBS	  treated	  hamsters	  (p	  <	  0.05).	  Additionally,	  ES-­‐specific	  IgA	  responses	  were	  
observed	  in	  both	  mucosal	  compartments	  of	  animals	  immunized	  with	  PBS	  and	  c-­‐di-­‐AMP,	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suggesting	  primary	  infection	  alone	  elicits	  local	  and	  distal	  antigen-­‐specific	  mucosal	  IgA	  











































Figure	  10.	  Kinetic	  analysis	  of	  anti-­‐ES	  IgG	  responses	  in	  sera	  of	  Syrian	  golden	  hamsters	  immunized	  
on	  days	  0,	  14,	  and	  28	  with	  PBS	  (control),	  15	  µg/dose	  c-­‐di-­‐AMP	  (adjuvant),	  100	  µg/dose	  A.	  
ceylanicum	  excretory-­‐secretory	  (ES)	  proteins,	  or	  100	  µg/dose	  ES	  co-­‐administered	  with	  15	  
µg/dose	  c-­‐di-­‐AMP	  by	  the	  intranasal	  route	  (n	  =	  5,	  per	  group).	  On	  day	  35	  animals	  were	  orally	  
infected	  with	  100	  third-­‐stage	  A.	  ceylanicum	  larvae	  (L3).	  Sera	  was	  collected	  from	  animals,	  pooled	  
















Figure	  11.	  Analysis	  of	  mucosal	  anti-­‐ES	  IgA	  responses	  of	  Syrian	  golden	  hamsters	  immunized	  on	  
days	  0,	  14,	  and	  28	  with	  PBS	  (control),	  15	  µg/dose	  c-­‐di-­‐AMP	  (adjuvant),	  100	  µg/dose	  A.	  
ceylanicum	  excretory-­‐secretory	  (ES)	  proteins,	  or	  with	  100	  µg/dose	  ES	  co-­‐administered	  with	  15	  
µg/dose	  c-­‐di-­‐AMP	  by	  the	  intranasal	  route	  (n	  =	  5,	  per	  group).	  On	  day	  35	  animals	  were	  orally	  
infected	  with	  100	  third-­‐stage	  A.	  ceylanicum	  larvae	  (L3).	  Upon	  development	  of	  adult	  worms,	  22	  
days	  post-­‐infection,	  the	  animals	  were	  euthanized	  and	  lung	  lavage	  (LL)	  and	  intestinal	  flush	  (IF)	  
samples	  were	  analyzed	  by	  ELISA.	  Significant	  with	  respect	  to	  PBS,	  infected	  hamsters	  (*,	  p	  <	  
0.05).	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5.2.2.	  Intranasal	  immunization	  with	  unadjuvated	  ES	  appears	  to	  modulate	  the	  severity	  of	  
hookworm-­‐associated	  weight	  loss	  and	  anemia	  
	  
To	  determine	  whether	  immunization	  with	  ES	  plus	  c-­‐di-­‐AMP	  could	  protect	  animals	  from	  
hookworm-­‐associated	  pathology,	  one	  week	  after	  the	  final	  immunization	  hamsters	  were	  
challenged	  with	  100	  L3	  larvae	  and	  observed	  for	  22	  days.	  	  
As	  expected,	  untreated,	  uninfected	  control	  hamsters	  (mean	  weight,	  108.0	  ±	  4.9	  g	  at	  
0	  dpi)	  steadily	  increased	  in	  weight	  throughout	  the	  experiment,	  reaching	  a	  mean	  of	  113.9%	  
of	  their	  initial	  (0	  dpi)	  weight	  by	  22	  dpi.	  	  For	  most	  of	  the	  infected	  groups,	  by	  14	  days	  after	  
challenge	  weight	  decline	  was	  observed.	  The	  most	  dramatic	  reductions	  occurred	  in	  the	  
groups	  without	  ES	  (PBS	  and	  c-­‐di-­‐AMP	  alone).	  In	  the	  PBS	  group	  (mean	  weight,	  123.5	  ±	  2.0	  g	  
at	  0	  dpi),	  weights	  declined	  from	  a	  mean	  of	  116.6%	  at	  11	  dpi	  to	  106.4%	  of	  their	  initial	  (0	  
dpi)	  weight	  by	  22	  dpi.	  Similarly,	  in	  the	  c-­‐di-­‐AMP	  alone	  group	  (mean	  weight,	  112.3	  ±	  4.3	  g	  at	  
0	  dpi),	  weights	  declined	  from	  a	  mean	  of	  113.9%	  at	  11	  dpi	  to	  102.5%	  of	  their	  initial	  weight	  
by	  22	  dpi.	  Weight	  decline	  was	  less	  pronounced	  in	  the	  ES	  +	  c-­‐di-­‐AMP	  group	  (mean	  weight,	  
110.0	  ±	  6.1	  g	  at	  0	  dpi),	  but	  still	  apparent.	  Here,	  weights	  declined	  from	  a	  mean	  of	  113.9%	  at	  
11	  dpi	  to	  107.6%	  of	  their	  initial	  weight	  by	  22	  dpi.	  Unlike	  the	  other	  groups,	  the	  ES	  alone	  
group	  (mean	  weight,	  118.0	  ±	  1.5	  g	  at	  0	  dpi)	  appeared	  relatively	  refractory	  to	  hookworm-­‐
associated	  weight	  loss,	  with	  weights	  stabilizing	  around	  110%	  of	  their	  initial	  weight	  from	  11	  
dpi	  to	  22	  dpi,	  the	  period	  the	  other	  groups	  were	  experiencing	  profound	  weight	  declines	  (Fig.	  
12A-­‐B).	  
Hemoglobin	  levels	  in	  untreated,	  uninfected	  control	  hamsters	  remained	  relatively	  
stable.	  In	  all	  the	  infected	  groups,	  however,	  by	  11	  days	  post-­‐challenge	  blood	  hemoglobin	  
levels	  began	  to	  steadily	  drop,	  declining	  approximately	  40%	  by	  18	  dpi.	  In	  contrast	  to	  the	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other	  infected	  groups,	  the	  ES	  alone	  group	  appeared	  to	  be	  recovering	  from	  hookworm-­‐
associated	  anemia	  by	  the	  final	  time-­‐point	  (22	  dpi).	  At	  this	  time,	  the	  ES	  alone	  group	  was	  
only	  experiencing	  an	  approximately	  25%	  reduction	  from	  pre-­‐challenge	  hemoglobin	  levels,	  
while	  the	  other	  groups	  remained	  depressed	  around	  40%	  (Fig.	  12C-­‐D).	  
	  
5.2.3.	  Intranasal	  immunization	  with	  unadjuvated	  ES	  reduces	  worm	  burden	  and	  egg	  excretion	  
To	  determine	  whether	  response	  to	  immunization	  had	  an	  impact	  on	  worm	  development,	  
animals	  were	  sacrificed	  22	  days	  post-­‐infection	  and	  parasites	  and	  eggs	  were	  counted.	  Mean	  
intestinal	  worm	  burdens	  were	  similar	  in	  the	  PBS	  (45.8	  ±	  6.1	  parasites)	  and	  c-­‐di-­‐AMP	  alone	  
(43.8	  ±	  4.6	  parasites)	  groups.	  However,	  compared	  to	  untreated	  control	  animals,	  the	  ES	  
alone	  group	  saw	  a	  73.8%	  reduction	  (p-­‐value	  <	  0.01)	  in	  mean	  intestinal	  worm	  burden	  (12.0	  
±	  4.7	  parasites).	  A	  non-­‐statistically	  significant	  46.7%	  reduction	  in	  mean	  worm	  burden	  was	  
observed	  in	  the	  ES	  +	  c-­‐di-­‐AMP	  group	  (24.4	  ±	  8.6	  parasites)	  (Fig.	  13A).	  Using	  fecal	  egg	  
counts	  as	  an	  additional	  marker	  of	  infection	  intensity;	  these	  data	  largely	  corroborated	  the	  
intestinal	  worm	  burden	  results.	  Here	  again,	  counts	  were	  highest	  in	  the	  PBS	  and	  c-­‐di-­‐AMP	  
alone	  groups,	  and	  lowest	  in	  the	  groups	  receiving	  ES.	  ES	  alone	  showed	  a	  67.4%	  reduction	  
(p-­‐value	  <	  0.001)	  in	  fecal	  eggs	  per	  gram	  (EPG),	  while	  the	  ES	  +	  c-­‐di-­‐AMP	  group	  showed	  a	  






























Figure	  12.	  One	  week	  following	  the	  final	  immunization	  animals	  were	  orally	  infected	  with	  100	  L3	  
A.	  ceylanicum	  larvae.	  Post-­‐infection	  weights	  with	  (A)	  and	  without	  (B)	  adjuvant.	  Post-­‐infection	  
blood	  hemoglobin	  levels	  with	  (C)	  and	  without	  (D)	  adjuvant.	  All	  values	  are	  means	  ±	  standard	  
errors	  of	  the	  means.	  
	  

























Figure	  13.	  Upon	  development	  of	  adult	  worms,	  22	  days	  post-­‐infection,	  the	  animals	  were	  
euthanized	  and	  small	  and	  large	  intestines	  removed.	  (A)	  Intestinal	  worm	  burdens	  for	  each	  animal	  
are	  indicated	  by	  a	  dot,	  with	  the	  group	  mean	  indicated	  by	  a	  horizontal	  line.	  (B)	  The	  McMaster	  
technique	  was	  used	  to	  calculate	  fecal	  egg	  counts.	  Fecal	  eggs	  per	  gram	  (EPG)	  for	  each	  animal	  are	  
indicated	  by	  a	  dot,	  with	  the	  group	  mean	  indicated	  by	  a	  horizontal	  line.	  
	  
73.8%	  reduction	  (p	  <	  0.01)	   67.4%	  reduction	  (p	  <	  0.001)	  
47.7%	  reduction	  (p	  <	  0.05)	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6.	  Discussion	  
Most	  pathogens	  invade	  their	  human	  host	  or	  establish	  infection	  at	  mucosal	  surfaces.1,	  2,	  3	  
However,	  the	  majority	  of	  existing	  vaccines	  are	  administered	  by	  parenteral	  injection.	  In	  
contrast	  to	  these	  vaccines,	  mucosal	  vaccinations	  have	  the	  potential	  to	  counter	  mucosa-­‐
associated	  pathogens	  at	  the	  portal	  of	  entry	  by	  inducing	  local	  pathogen-­‐specific	  immune	  
responses,	  as	  well	  as	  systemic	  humoral	  and	  cellular	  responses.	  Additionally,	  targeting	  
mucosal	  sites	  also	  has	  the	  potential	  to	  induce	  immune	  responses	  at	  other,	  remote,	  mucosal	  
surfaces;	  and	  may	  offer	  logistical	  advantages	  over	  parenteral	  vaccination,	  such	  as	  increased	  
patient	  compliance	  due	  to	  ease	  of	  administration.5	  
Despite	  these	  advantages,	  very	  few	  mucosal	  vaccines	  are	  licensed	  for	  human	  use,	  
with	  even	  fewer	  available	  for	  use	  in	  the	  US	  (Table	  1).	  This	  is	  partially	  due	  to	  the	  public’s	  
increasing	  demand	  for	  safer	  vaccines,	  which	  has	  led	  to	  an	  increased	  use	  of	  highly	  purified	  
recombinant	  molecules	  or	  pathogen	  subunits.	  While	  the	  use	  of	  well-­‐defined	  protective	  
antigens	  has	  significantly	  improved	  the	  safety	  profile	  of	  vaccine	  antigens,	  these	  antigens	  
usually	  lack	  inherent	  immunostimulatory	  properties,	  and	  typically	  do	  not	  elicit	  strong	  
immune	  responses.	  The	  development	  of	  effective	  mucosal	  vaccines	  is	  further	  challenged	  by	  
the	  unique	  characteristics	  of	  the	  mucosal	  environment,	  including	  the	  presence	  of	  mucus,	  
limited	  antigen	  uptake,	  and	  the	  possibility	  of	  antigen	  degradation.5	  As	  a	  result	  of	  these	  
factors	  mucosal	  adjuvants	  need	  to	  be	  incorporated	  into	  the	  formulation	  to	  improve	  a	  
vaccine’s	  efficacy.20	  	  
Unfortunately,	  only	  a	  few	  adjuvants	  are	  currently	  licensed	  for	  human	  use	  (Alum,	  
AS04,	  and	  MF59),	  with	  none	  of	  them	  especially	  effective	  when	  delivered	  mucosally.14,	  9	  The	  
lack	  of	  effective	  mucosal	  adjuvants,	  therefore,	  represents	  a	  bottleneck	  in	  the	  development	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of	  mucosal	  vaccines,	  and	  thus,	  is	  an	  important	  priority.5,	  9	  As	  novel	  candidate	  adjuvants	  are	  
investigated,	  it	  is	  important	  to	  consider	  that	  adjuvants	  not	  only	  enhance	  the	  strength	  of	  the	  
elicited	  antigen-­‐specific	  responses,	  but	  also	  may	  exhibit	  intrinsic	  immunomodulatory	  
properties.	  In	  this	  context,	  stimulation	  of	  the	  appropriate	  type	  of	  immune	  response	  is	  a	  key,	  
as	  eliciting	  an	  incorrect	  type	  of	  immune	  response	  could	  lead	  to	  immunopathology	  or	  even	  
exacerbate	  disease.20	  In	  the	  present	  studies,	  we	  evaluated	  the	  mucosal	  adjuvant	  properties	  
of	  c-­‐di-­‐AMP,	  a	  member	  of	  the	  cyclic	  di-­‐nucleotide	  family,	  in	  combination	  with	  a	  single	  
recombinant	  antigen,	  and	  in	  an	  infectious	  disease	  model	  using	  native	  soluble	  pathogen	  
proteins.	  
The	  mechanism	  of	  action	  of	  c-­‐di-­‐nucleotides	  is	  still	  unknown;	  however,	  it	  has	  been	  
speculated	  that	  they	  might	  act	  through	  putative	  DNA/RNA	  receptors	  which	  activate	  an	  
intracellular	  signal	  transduction	  cascade.	  This	  in	  turn	  might	  regulate	  the	  expression	  of	  
genes	  promoting	  a	  local	  pro-­‐inflammatory	  environment	  that	  leads	  to	  the	  mobilization,	  
recruitment	  and	  activation	  of	  antigen	  presenting	  cells.9	  From	  our	  studies,	  c-­‐di-­‐AMP	  
stimulates	  strong	  humoral	  (Figs.	  2-­‐3)	  and	  cellular	  immune	  responses	  (Fig.	  4),	  and	  induces	  a	  
mixed	  Th1/Th2/Th17,	  but	  predominately	  Th1/Th17	  T	  cell	  response	  pattern,	  as	  shown	  by	  
elevated	  expression	  of	  IgG2a	  (Fig.	  5)	  and	  enhanced	  secretion	  of	  IFN-­‐γ,	  IL-­‐17,	  and	  IL-­‐22	  (Fig.	  
6-­‐9).	  
	  We	  also	  observed	  comparable	  results	  through	  the	  intranasal	  and	  sublingual	  routes.	  
The	  recent	  association	  between	  an	  inactivated	  intranasal	  influenza	  vaccine	  and	  Bell’s	  palsy	  
has	  raised	  concerns	  of	  the	  possibility	  of	  retrograde	  passage	  of	  inhaled	  antigens	  or	  
adjuvants	  through	  the	  olfactory	  epithelium,	  and	  prompted	  research	  into	  alternative	  routes	  
of	  mucosal	  immunization.3,	  28	  	  Given	  the	  comparability	  of	  our	  results,	  this	  study	  adds	  to	  a	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growing	  body	  of	  literature	  suggesting	  that	  sublingual	  immunization	  can	  result	  in	  responses	  
comparable	  to	  nasal	  immunization	  regarding	  the	  magnitude,	  breadth	  and	  anatomic	  
dissemination	  of	  induced	  immune	  responses.3	  
When	  investigating	  the	  effect	  of	  c-­‐di-­‐AMP	  on	  the	  expression	  of	  IgG	  isotypes	  (IgG1,	  
IgG2a,	  and	  IgG2b),	  co-­‐administration	  of	  c-­‐di-­‐AMP	  with	  antigen	  resulted	  in	  the	  greatest	  
enhancement	  of	  IgG2a	  (503-­‐fold	  [s.l.]	  and	  445-­‐fold	  [i.n.]);	  and	  the	  least	  enhancement	  of	  
IgG1	  (8-­‐fold	  [s.l.]	  and	  11-­‐fold	  [i.n.]),	  as	  compared	  to	  antigen	  alone.	  These	  data	  indicate	  that	  
by	  both	  routes	  c-­‐di-­‐AMP	  is	  predominately	  associated	  with	  a	  CD4+	  T	  helper	  1	  (Th1)	  
response,	  as	  IgG1	  and	  IgG2a	  isotypes	  are	  broadly	  associated	  with	  Th2	  and	  Th1	  T	  cell	  
responses	  in	  mice,	  respectively.29	  The	  development	  of	  enhanced	  IgG2a	  responses	  is	  
supported	  by	  measurements	  of	  cytokine	  secreting	  cells	  (Figure	  6-­‐7)	  and	  cytokine	  
concentrations	  (Figure	  8-­‐9),	  which	  showed	  stronger	  expression	  of	  IFN-­‐γ	  (Th1)	  than	  IL-­‐4	  
(Th2).	  A	  large	  body	  of	  literature	  suggests	  that	  the	  cytokines	  IL-­‐4,	  IFN-­‐γ	  and	  TGF-­‐β	  regulate	  
immunoglobulin	  class	  switching	  through	  transcriptional	  regulation.30,	  31,	  32	  Evidence	  
indicates	  that	  the	  Th2-­‐specific	  cytokine,	  IL-­‐4,	  induces	  switching	  to	  IgG1	  and	  IgE,	  and	  
inhibits	  switching	  to	  IgG2b.	  In	  contrast,	  the	  Th1-­‐specific	  cytokine,	  IFN-­‐γ,	  has	  been	  shown	  to	  
inhibit	  the	  IL-­‐4-­‐mediated	  induction	  of	  IgG1	  and	  IgE,	  and	  to	  enhance	  the	  production	  of	  
IgG2a.31	  Additionally,	  TGF-­‐β	  has	  the	  ability	  to	  direct	  class	  switching	  to	  IgA	  and	  IgG2b.32	  
In	  addition	  to	  IFN-­‐γ,	  IL-­‐17	  (Figs.	  6-­‐9)	  and	  IL-­‐22	  (Figs.	  8-­‐9)	  were	  also	  enhanced	  
through	  vaccination	  with	  c-­‐di-­‐AMP	  as	  adjuvant.	  It	  is	  well	  established	  that	  Th1	  cells	  produce	  
IFN-­‐γ	  and	  TNF-­‐β,	  which	  activate	  macrophages	  and	  are	  involved	  in	  delayed-­‐type	  
hypersensitivity	  reactions;	  and	  that	  Th2	  cells	  produce	  IL-­‐4,	  IL-­‐5,	  IL-­‐10	  and	  IL-­‐13,	  which	  are	  
responsible	  for	  strong	  antibody	  responses,	  including	  IgE	  production,	  and	  the	  inhibition	  of	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several	  macrophage	  functions.33	  Recently,	  Th17	  cells	  have	  been	  identified	  as	  a	  third	  T	  
helper	  lineage	  that	  regulates	  inflammation	  via	  production	  of	  distinct	  cytokines,	  such	  as	  IL-­‐
17,	  IL-­‐17F,	  IL-­‐21,	  and	  IL-­‐22.34,	  35	  There	  is	  growing	  evidence	  that	  Th17	  cells,	  and	  other	  IL-­‐
17-­‐producing	  cells,	  are	  critical	  for	  host	  defense	  against	  bacterial,	  fungal,	  and	  viral	  infections	  
at	  mucosal	  surfaces.36	  While	  the	  role	  of	  IL-­‐17	  in	  vaccine-­‐induced	  immunity	  against	  
eukaryotic	  parasites	  is	  not	  fully	  defined,	  there	  is	  evidence	  that	  induction	  of	  IL-­‐17	  may	  be	  
important	  for	  protection	  against	  parasite	  pathogens,	  such	  as	  Leishmania	  donovani,	  Eimeria	  
maxima,	  and	  Nippostrongylus	  brasiliensis.	  As	  reviewed	  by	  Lin	  et	  al	  35,	  production	  of	  IL-­‐17	  
and	  IL-­‐22	  in	  human	  subjects	  showed	  a	  strong	  and	  independent	  association	  with	  protection	  
against	  Kala	  azar,	  or	  visceral	  leishmaniasis,	  the	  disease	  caused	  by	  infection	  with	  L.	  
donovani.	  Furthermore,	  inclusion	  of	  IL-­‐17	  as	  an	  adjuvant	  along	  with	  a	  purified	  recombinant	  
protein	  vaccine	  was	  shown	  to	  reduce	  oocyte	  shedding	  and	  induce	  protection	  against	  the	  
parasite	  Eimeria	  acervulina	  in	  chickens.	  In	  our	  study,	  infection	  of	  hamsters	  with	  Acylostoma	  
ceylanicum	  was	  used	  as	  model	  of	  intestinal	  hookworm	  infection;	  however,	  infection	  of	  mice	  
with	  the	  rodent	  hookworm,	  Nippostrongylus	  brasiliensis,	  is	  another	  widely	  used	  model.37	  In	  
a	  study	  by	  Liu	  et	  al	  38,	  the	  authors	  suggest	  during	  migration	  through	  the	  lung	  N.	  brasiliensis	  
elicits	  multiple	  mechanisms	  to	  down-­‐regulate	  local	  IL-­‐17	  and	  control	  inflammatory	  cell	  
infiltration.	  Together,	  these	  studies	  suggest	  IL-­‐17	  may	  have	  an	  important	  role	  in	  induction	  
of	  Th17	  memory	  responses	  and	  could	  be	  a	  potential	  target	  in	  the	  design	  of	  effective	  
vaccines	  against	  parasites.35	  
The	  encouraging	  performance	  of	  c-­‐di-­‐AMP	  in	  these	  initial	  studies	  led	  us	  to	  test	  it	  as	  a	  
mucosal	  adjuvant	  in	  a	  vaccine	  model	  of	  A.	  ceylanicum	  pathogenesis.	  Contrary	  to	  our	  
hypothesis,	  however,	  c-­‐di-­‐AMP	  did	  not	  significantly	  enhance	  the	  protective	  efficacy	  of	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hookworm	  excretory-­‐secretory	  (ES)	  antigens.	  In	  Figure	  12B,	  we	  show	  that	  hamsters	  
vaccinated	  intranasally	  with	  ES	  antigens	  alone	  are	  partially	  protected	  from	  hookworm-­‐
associated	  weight	  loss,	  and	  these	  hamsters	  exhibited	  a	  trend	  toward	  recovery	  from	  
hookworm-­‐associated	  anemia	  by	  22	  days	  post-­‐infection	  (Figure	  12D).	  Similar	  findings	  
were	  not	  present	  in	  any	  of	  the	  other	  groups,	  including	  the	  ES	  plus	  c-­‐di-­‐AMP	  group	  (Figure	  
12A,	  C).	  	  In	  figure	  13A,	  we	  show	  that	  ES	  alone	  confers	  a	  73.8%	  reduction	  (p-­‐value	  <	  0.01)	  in	  
worm	  burden,	  and	  ES	  co-­‐administered	  with	  c-­‐di-­‐AMP	  only	  confers	  a	  46.7%	  reduction	  (NS),	  
as	  compared	  to	  animals	  vaccinated	  with	  PBS.	  Using	  fecal	  egg	  counts	  as	  an	  additional	  
marker	  of	  infection	  intensity,	  we	  saw	  similar	  levels	  of	  reduction,	  67.4%	  (p-­‐value	  <	  0.001)	  
for	  ES	  alone	  versus	  47.7%	  (p-­‐value	  <	  0.05)	  for	  ES	  plus	  c-­‐di-­‐AMP	  (Figure	  13B),	  compared	  to	  
PBS	  vaccinated	  controls.	  The	  comparability	  of	  adult	  worm	  burdens	  and	  egg	  counts	  
provides	  further	  evidence	  of	  the	  validity	  of	  egg	  counts	  as	  a	  marker	  of	  infection	  intensity.	  	  	  	  
	   In	  the	  hamster	  model,	  our	  finding	  of	  a	  73.8%	  reduction	  in	  adult	  worm	  burden	  is	  
similar	  to	  a	  study	  by	  Khan	  et	  al	  39	  that	  showed	  a	  67.0%	  reduction	  following	  intramuscular	  
immunization	  with	  ES.	  In	  that	  study,	  the	  authors	  immunized	  male	  hamsters	  
intramuscularly	  with	  three	  doses	  of	  ES	  (30,	  60,	  120	  µg),	  using	  Freund’s	  Complete	  Adjuvant	  
co-­‐administered	  with	  the	  first	  dose,	  and	  challenged	  7	  days	  after	  the	  final	  dose	  with	  A.	  
ceylanicum	  (65	  ±	  10	  L3).	  	  The	  authors	  reported	  a	  pre-­‐challenge	  ES-­‐specific	  serum	  IgG	  titer	  
of	  1:1,600	  that	  correlated	  with	  protection;	  however,	  a	  definitive	  role	  of	  antigen-­‐specific	  
serum	  IgG	  was	  not	  established.	  	  In	  the	  Khan	  et	  al	  study,	  no	  data	  on	  hook-­‐worm	  associated	  
pathology	  were	  presented;	  however,	  a	  study	  by	  Bungiro	  et	  al	  46,	  showed	  that	  3	  
subcutaneous	  immunizations	  (21-­‐day	  intervals)	  with	  native	  ES	  products	  adsorbed	  to	  alum	  
significantly	  reduced	  hookworm-­‐associated	  anemia	  and	  weight	  loss	  (worm	  burden	  not	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assessed).	  Furthermore,	  we	  demonstrate	  enhanced	  protection	  to	  a	  mucosal	  immunization	  
study	  by	  Fairfax	  et	  al	  40	  where	  the	  authors	  cloned	  and	  orally	  immunized	  hamsters	  with	  
three	  doses	  of	  A.	  ceylanicum	  FAR-­‐1	  (AceFAR-­‐1),	  a	  hookworm	  orthologue	  belonging	  to	  the	  
nematode	  fatty	  acid	  and	  retinol	  (FAR)	  binding	  family	  found	  in	  ES.	  In	  that	  study,	  Fairfax	  et	  al	  
reported	  47%	  reduction	  in	  mean	  intestinal	  worm	  burden	  21	  days	  post-­‐infection	  when	  3	  
doses	  of	  AceFAR-­‐1	  (100	  µg)	  were	  co-­‐administered	  with	  cholera	  toxin	  (10	  µg)	  at	  14	  day	  
intervals	  (data	  on	  antibody	  titers	  was	  not	  presented).	  
As	  shown	  in	  Figure	  10,	  through	  intranasal	  immunization	  we	  were	  able	  to	  induce	  a	  
pre-­‐challenge	  serum	  antigen-­‐specific	  IgG	  titer	  (1:1,100)	  that	  was	  enhanced	  following	  
primary	  infection	  (1:7,400);	  similar	  responses	  were	  observed	  with	  and	  without	  adjuvant.	  
As	  Figure	  11	  shows,	  intranasal	  immunization	  with	  ES	  also	  enhanced	  post-­‐challenge	  
antigen-­‐specific	  mucosal	  IgA	  responses.	  Responses	  in	  animals	  vaccinated	  with	  ES	  alone	  
showed	  significant	  enhancement	  of	  intestinal	  anti-­‐ES	  IgA	  responses,	  as	  compared	  to	  
vaccination	  with	  PBS;	  suggesting	  intranasal	  administration	  of	  antigens	  primes	  intestinal	  
antigen-­‐specific	  IgA	  responses.	  	  
In	  non-­‐ES	  vaccinated	  hamsters,	  anti-­‐ES	  serum	  IgG	  responses	  were	  negative	  pre-­‐
challenge	  and	  stimulated	  during	  primary	  infection	  (1:1,000)	  (Fig.	  10).	  Additionally,	  ES-­‐
specific	  IgA	  responses	  were	  detectable	  in	  lung	  and	  intestinal	  samples,	  following	  primary	  
infection	  of	  non-­‐ES	  vaccinated	  hamsters	  (Fig.	  11).	  In	  our	  model,	  hamsters	  are	  orally	  
infected	  with	  A.	  ceylanicum	  with	  the	  assumption	  that	  larvae	  migrate	  directly	  to	  the	  small	  
intestine	  (without	  migration	  through	  the	  circulatory	  system	  and/or	  lungs)	  where	  they	  
mature	  into	  blood-­‐feeding,	  egg-­‐laying	  adults.	  In	  1972,	  Ray	  et	  al	  41	  provided	  strong	  evidence	  
in	  support	  of	  this	  assumption.	  Together,	  this	  suggests	  primary	  infection	  with	  A.	  ceylanicum	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induces	  local	  (i.e.,	  intestinal)	  and	  distal	  (i.e.,	  lung)	  anti-­‐ES	  IgA	  responses.	  These	  results	  are	  
in	  general	  agreement	  and	  extend	  findings	  made	  by	  Bungiro	  et	  al	  25	  that	  showed	  ES-­‐specific	  
IgA	  responses	  in	  naïve	  hamsters	  were	  detectable	  in	  fecal	  and	  intestinal	  flush	  samples	  41	  
days	  post-­‐infection.	  To	  our	  knowledge,	  this	  is	  the	  first	  study	  to	  report	  stimulation	  of	  lung-­‐
associated	  antigen-­‐specific	  IgA	  following	  primary	  infection	  in	  this	  model.	  Although	  the	  
relevance	  of	  hookworm-­‐specific	  mucosal	  IgA	  to	  protection	  has	  not	  been	  established,	  IgA	  
has	  been	  hypothesized	  to	  target	  the	  parasite	  by	  mechanisms	  such	  as	  neutralization	  of	  
secretory	  molecules	  and/or	  induction	  of	  eosinophil	  degranulation.25	  	  
In	  humans,	  the	  normal	  hookworm	  life-­‐cycle	  involves	  migration	  of	  L3	  parasites	  
through	  the	  lungs;	  therefore,	  stimulation	  of	  lung-­‐associated	  immune	  responses,	  including	  
antigen-­‐specific	  IgA,	  could	  block	  parasite	  migration	  and	  the	  subsequent	  clinical	  sequelae.	  
Recently,	  Harvie	  et	  al	  42	  demonstrated	  this	  by	  showing	  a	  lung-­‐initiated,	  CD4+	  T-­‐cell-­‐
dependent	  and	  IL-­‐4-­‐	  and	  STAT6-­‐dependent,	  immune	  response	  in	  mice	  was	  sufficient	  to	  
confer	  protection	  against	  reinfection	  with	  N.	  brasiliensis.	  	  Furthermore,	  Tsuji	  et	  al	  43	  has	  
reported	  an	  intranasal	  vaccine	  against	  Ascaris	  suum	  that	  induced	  lung	  (antigen-­‐specific	  
IgA)	  and	  systemic	  (antigen-­‐specific	  IgG	  and	  IgE)	  immune	  responses	  that	  were	  correlated	  
with	  reduced	  larval	  migration	  through	  the	  lungs.	  	  
When	  given	  intranasally,	  ES	  alone	  appears	  to	  be	  highly	  immunogenic	  and	  able	  to	  
induce	  a	  protective	  immune	  response.	  A	  characteristic	  feature	  of	  helminth	  infection	  is	  a	  
Th2-­‐dominated	  immune	  response,	  but	  stimulation	  of	  immunoregulatory	  cell	  populations,	  
such	  as	  regulatory	  T	  cells	  and	  alternatively	  activated	  macrophages,	  is	  also	  common.	  
Typically,	  Th1/17	  immunity	  is	  blocked	  and	  productive	  effector	  responses	  are	  muted,	  
allowing	  survival	  of	  the	  parasite	  in	  a	  modified	  Th2	  environment.37	  Likely,	  ES	  contains	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adjuvant	  properties	  that	  modulate	  the	  immune	  response	  to	  its	  vaccine	  relevant	  antigens.	  
The	  ES	  used	  in	  this	  study	  was	  prepared	  by	  incubating	  live	  adult	  worms	  in	  PBS	  for	  6	  hours	  
at	  37	  °C.	  As	  a	  result,	  it	  probably	  contains	  known	  TLR	  ligands,	  such	  as	  bacterial	  lipopeptide	  
(TLR-­‐2),	  lipopolysaccharide	  (TLR-­‐4),	  flagellin	  (TLR-­‐5),	  CpG	  DNA	  (TLR-­‐9)	  and	  others,	  many	  
of	  which	  are	  currently	  being	  investigated	  as	  adjuvants.	  Additionally,	  ES	  might	  contain	  
intrinsic	  molecules	  able	  to	  act	  as	  adjuvants.	  MacDonald	  et	  al	  29	  recently	  produced	  a	  
recombinant	  version	  of	  an	  Onchocerca	  volvulus	  excretory-­‐secretory	  protein	  called	  ASP-­‐1	  
and	  demonstrated	  its	  ability	  to	  augment	  Th1/Th2	  responses.	  Others	  have	  shown	  the	  ability	  
of	  ES	  proteins	  of	  adult	  Nippostrongylus	  brasiliensis	  and	  Heligmosomoides	  polygyrus	  to	  act	  as	  
Th2	  adjuvants	  to	  bystander	  proteins.37,	  48	  Given	  the	  protective	  phenotype	  ES	  seemed	  to	  
induce	  in	  our	  study,	  future	  studies	  should	  attempt	  to	  characterize	  the	  T	  helper	  response	  
elicited	  by	  ES,	  as	  this	  could	  be	  helpful	  in	  future	  vaccine	  development.	  
As	  noted	  previously,	  IL-­‐17	  might	  have	  a	  protective	  role	  in	  vaccine-­‐induced	  
immunity	  to	  parasites.	  However,	  IL-­‐17-­‐producing	  CD4+	  T	  cells	  have	  also	  been	  implicated	  in	  
tissue	  pathology	  associated	  with	  schistosomiasis,	  demonstrating	  this	  sub-­‐population	  of	  T	  
helper	  cells	  is	  also	  capable	  of	  driving	  adverse	  inflammatory	  reactions	  to	  helminth	  parasites.	  
Rutitzky	  et	  al	  44,	  45	  reported	  that	  IL-­‐17	  exacerbates	  pathology	  by	  recruiting	  neutrophils	  to	  
the	  site	  of	  infection	  contributing	  to	  the	  development	  of	  severe	  schistosome	  egg-­‐induced	  
immunopathology.	  In	  our	  study,	  it	  is	  possible	  that	  high	  levels	  of	  IL-­‐17,	  stimulated	  by	  c-­‐di-­‐
AMP,	  were	  negatively	  modulating	  the	  protective	  effect	  of	  ES,	  and	  causing	  local	  
inflammation	  of	  the	  small	  intestine.	  This	  is	  one	  explanation	  for	  why	  the	  ES	  plus	  adjuvant	  
group	  developed	  comparable	  hookworm-­‐associated	  weight	  loss	  and	  anemia	  to	  the	  PBS	  
group	  (Fig.	  12),	  despite	  having	  nearly	  half	  the	  worm	  burden	  of	  this	  group	  (24.4	  ±	  8.6	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parasites	  [ES	  +	  c-­‐di-­‐AMP]	  vs.	  45.8	  ±	  6.1	  parasites	  [PBS])(Fig.	  13).	  It	  was	  also	  curious	  that	  
vaccination	  with	  c-­‐di-­‐AMP	  alone	  seemed	  to	  dampen	  antigen-­‐specific	  lung	  IgA	  in	  response	  
to	  primary	  infection	  (Fig.	  11).	  We	  cannot	  provide	  a	  mechanism	  for	  this	  observation.	  
Previously,	  in	  vivo	  experiments	  were	  conducted	  using	  c-­‐di-­‐AMP	  alone,	  in	  all	  these	  studies	  
antigen-­‐specific	  humoral	  or	  cellular	  immune	  responses	  were	  never	  detected	  (data	  not	  
shown).	  	  
In	  addition	  to	  immunomodulatory	  properties,	  our	  study	  (as	  well	  as	  the	  work	  by	  
Khan	  et	  al	  and	  Bungiro	  et	  al)	  provides	  convincing	  evidence	  of	  the	  availability	  of	  protective	  
antigens	  within	  ES.	  In	  the	  Bungiro	  et	  al	  46	  study	  mentioned	  earlier,	  the	  authors	  also	  cloned	  
and	  orally	  immunized	  hamsters	  with	  Ancylostoma	  ceylanicum	  excretory-­‐secretory	  protein	  
2	  (AceES-­‐2),	  a	  highly	  immunoreactive	  protein	  found	  in	  ES.	  Following	  challenge	  infection,	  
they	  showed	  a	  significant	  reduction	  in	  hookworm-­‐associated	  anemia,	  but	  not	  weight	  loss	  
(worm	  burden	  was	  not	  assessed).	  Interestingly,	  antigen-­‐specific	  serum	  IgG	  responses	  were	  
not	  detected	  in	  this	  group,	  suggesting	  serum	  parasite-­‐specific	  responses	  are	  not	  absolutely	  
necessary	  for	  protection	  from	  hookworm	  associated	  pathology.	  Additionally,	  AceFAR-­‐1	  
(discussed	  above)	  and	  Ancylostoma	  ceylanicum	  Kunitz-­‐type	  inhibitor	  (AceKI)	  are	  two	  other	  
protective	  antigens	  that	  have	  been	  identified	  and	  isolated	  from	  ES.40,	  47	  Conversely	  to	  
AceES-­‐2,	  Chu	  et	  al	  47	  showed	  partial	  protection	  against	  hookworm-­‐associated	  growth	  delay	  
without	  a	  measurable	  effect	  on	  anemia	  when	  recombinant	  AceKI	  was	  given	  subcutaneously	  
(worm	  burden	  not	  assessed).	  Furthermore,	  the	  intranasal	  vaccine	  against	  A.	  suum	  
(mentioned	  earlier)	  uses	  an	  ES	  antigen	  called	  As16,	  which	  the	  authors	  have	  recombinantly	  
expressed	  in	  Escherichia	  coli.43	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In	  conclusion,	  c-­‐di-­‐AMP	  appears	  to	  be	  a	  promising	  Th1/Th17	  mucosal	  adjuvant	  with	  
robust	  immune	  responses	  observed	  through	  intranasal,	  as	  well	  as	  sublingual	  vaccination.	  
Despite	  these	  initial	  successes,	  however,	  c-­‐di-­‐AMP	  failed	  to	  significantly	  enhance	  the	  
protective	  efficacy	  of	  excretory-­‐secretory	  (ES)	  when	  tested	  in	  a	  vaccine	  model	  of	  
hookworm	  pathogenesis.	  Still	  important	  was	  the	  discovery	  that	  ES	  antigens	  alone,	  given	  
intranasally,	  confers	  a	  73.8%	  reduction	  in	  adult	  worm	  burden,	  and	  appear	  to	  modulate	  the	  
severity	  of	  hookworm-­‐associated	  anemia	  and	  weight	  loss.	  We	  hypothesize	  that	  part	  of	  this	  
success	  is	  due	  to	  inherent	  adjuvant	  properties	  of	  ES,	  which	  boost	  the	  immunogenicity	  of	  
vaccine	  relevant	  antigens.	  In	  these	  regards,	  future	  studies	  should	  be	  conducted	  to	  identify	  
both	  the	  protective	  antigens	  within	  ES	  and	  to	  characterize	  the	  adjuvant	  properties	  of	  ES.	  
Once	  the	  relevant	  protective	  antigens	  in	  ES	  are	  identified	  and	  isolated,	  a	  well-­‐defined	  
profile	  of	  the	  immunomodulatory	  characteristics	  of	  crude	  ES	  will	  be	  helpful	  in	  selection	  of	  
appropriate	  adjuvants.	  Taken	  together,	  the	  inability	  of	  c-­‐di-­‐AMP	  to	  enhance	  protective	  
efficacy	  in	  a	  model	  of	  hookworm	  pathogenesis	  does	  not	  rule	  out	  its	  future	  utility	  in	  other	  
models.	  If	  anything,	  these	  studies	  highlight	  the	  complexity	  of	  vaccine	  biology	  and	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